

Our Momentum Builds



strategy

expand the business

In fiscal 2004 we identified three internal operating strengths that can be leveraged to expand the business. We have broadened our business development initiatives to target other products and therapeutic classes. As a result, we've begun to expand our product offerings through internal R&D, marketing partnerships and acquisitions. Our product pipeline is growing, and we have four new products launching in fiscal 2006 with a market potential exceeding \$600 million.



milestones

'05

February 2004

Marketing partnership for platelet bacterial detection system in Europe

June 2004

Marketing partnership for surgical patient and blood/fluid warming system in Japan

June 2004

FDA clearance of filter-free, leukoreduced plasma collection bowl

July 2004

Marketing partnership for first non-invasive test for blood hematocrit

August 2004

Acquisition of Blood Stream® family of surgical products

September 2004

Declaration of conformity for European sale of cardioPAT® system

October 2004

Equity investment and research collaboration on separation system using nanotechnology

November 2004

FDA clearance of LOGIC blood inventory software enhancements

January 2005

FDA clearance of cardioPAT surgical blood salvage system

April 2005

FDA clearance of new protocol for ACP® 215 cell processing system

Table of Contents:

p.2-5: Shareholders' Letter p.6-7: Corporate Strategies p.8: Corporate Governance p.9: Financials

at a glance

product portfolios & markets

Donor Products

CORE TECHNOLOGY

We market our donor products to blood and plasma collection agencies worldwide. Each system automates the collection of specific blood components (plasma, platelets, or red cells), but they all operate in the same way. Blood is collected from a donor and flows into a centrifuge bowl which separates the blood into its components. The desired component is directed into a collection bag, and the remaining blood parts are returned to the donor. This process occurs in a sterile, closed-circuit, consumable set attached to our device.

■ PLASMA

Plasma is transfused to trauma or surgical patients. More often, though, plasma is used as a raw material by pharmaceutical companies to manufacture drugs like IVIG and Factor VIII.

Our PCS®2 system automates the collection of two units of plasma from one donor. Our technology improves customers' time and labor efficiencies, product yields, and donor safety. We also offer plasma customers data management software that automates their operations.

There remains increasing demand for plasma-derived pharmaceuticals, but there is still market volatility. Consolidation has resulted in closings of many plasma collection centers (our customers). An oversupply of plasma globally reduced the number of collections needed in the short term. It appears that in the U.S. and Europe supply is beginning to level with demand, but there are still over supplies in other parts of the world. We believe that the collection industry will eventually return to traditional growth rates of 2–4%.


■ BLOOD BANK

Platelets aid in clotting and are often transfused to cancer patients whose own platelets have been damaged by chemotherapy.


Our MCS® systems automate the collection of one to two "doses" of platelets from one donor. These "single donor platelets" benefit patients by minimizing exposure to certain transfusion risks. Our technology improves customers' efficiencies and product yields. It is also portable enough for use on mobile blood drives. The platelet collection market is mature, and increased collection efficiencies may offset future increased platelet demand.


Detecting bacteria in platelets is a growing trend as bacterial contamination poses significant risks to patients. Bacterial detection may negatively affect platelet supplies as testing uses some of the limited, five day shelf life of platelets. Blood collectors may strategically turn to mobile platelet collection to increase supplies. Cost issues may also drive increased automated platelet collections.

Plasma Disposable Sales
(Dollars in Millions)



Blood Bank Disposable Sales
(Dollars in Millions)





Patient Products


■ RED CELL

Red blood cells are the most frequently transfused blood component and are often given to surgical and trauma patients or patients with anemia-related diseases.

Our MCS systems automate the collection of two units of red cells from one donor. Our technology helps customers address operational challenges by improving efficiencies and yield while supporting regulatory compliance. Donors appreciate the ease of donation and the ability to help two patients with one donation.

Red cell shortages are a common problem plaguing healthcare systems. The ability to collect two units of red cells from one donor using our technology can have a significant positive effect on blood supplies. While our technology is taking hold in the U.S., automated collections with our system represent only 5% of the 15 million U.S. red cell collections done annually. Globally, this is a largely untapped market, and so we expect ongoing, rapid revenue growth from this product.

Red Cell Disposable Sales
(Dollars in Millions)



CORE TECHNOLOGY

We market our patient products to hospital surgical suites and service providers worldwide. Each product salvages blood lost by the patient, so he can get back his own blood rather than receive a transfusion of unknown donor blood. We market our products for different surgeries, but each product operates in the same way. Blood is suctioned from a wound site, collected in a centrifuge, and cleaned. The blood is transferred to a collection bag and made available for transfusion back to the patient. This process occurs in a sterile, closed-circuit, consumable set attached to our device.


■ SURGICAL

Our surgical blood salvage products reduce or eliminate a patient's dependence on donated blood as transfusions of donor blood carries risks. Blood shortages and rising blood prices have reinforced the benefits of surgical blood salvage.

Our Cell Saver® system is targeted to rapid and high volume blood loss surgeries. This is a mature market which is declining in the U.S. due to improved surgical techniques minimizing blood loss and new technology reducing the number of open heart surgeries.

Our OrthoPAT® system targets orthopedic surgeries with slower, lower volume blood loss that often occurs well after surgery. The OrthoPAT system offers significant advantages over other technologies which cannot salvage blood lost after the surgery. Thus, we have little competition. This is a large, emerging market that we are only just beginning to penetrate. OrthoPAT sales are driving patient business growth.

Surgical Disposable Sales
(Dollars in Millions)




improve profitability

Through discipline in operations management, we have improved the profitability of the Company over the past two years. We are extending our operational effectiveness discipline beyond the factories and are implementing fundamental changes in the way we run the business to generate long-term, consistent positive drop-through on our P&L.


FINANCIAL HIGHLIGHTS

<i>\$ in millions, except share data</i>	2001	2002	2003	2004	2005
Net revenues	\$ 294	\$ 320	\$ 337	\$ 364	\$ 384
Gross profit	142	155	155	174	198
R&D expenses	19	20	20	17	20
Total operating expenses	129	118	117	126	138
Operating income	13	36	37	47	60
Net income	\$ 7	\$ 30	\$ 28	\$ 29	\$ 40
Net income per share (diluted)	\$0.28	\$1.11	\$1.13	\$1.19	\$1.52
Cash flow from operations	\$ 57	\$ 33	\$ 47	\$ 77	\$ 71
Cash and short-term investments	74	68	50	118	186
Debt	70	72	71	58	46


Revenue Growth
(Percent Over Prior Year)



Gross Margin
(Percent of Sales)



Operating Margin
(Percent of Sales)





TO OUR SHAREHOLDERS,

2004 was another dynamic year for the financial community and public companies as new regulations for financial reporting and accountability were implemented to support transparency and strong corporate governance. At Haemonetics, we remain committed to the highest standards in governance, financial reporting, and investor communications.

Last year, we shared that Haemonetics had begun to transition and reposition your Company for continued financial stability and business expansion. We exit fiscal year 2005 having made concrete progress towards these goals.

- We gained Board approval on and are now operating to a five-year strategic plan with two areas of focus: improved profitability and expanding the business.

Improved profitability—Through discipline in operations management, we achieved our financial targets for FY05 as well as a key milestone. Gross margin grew 400 basis points over FY04 to 51.6%; expenses were controlled at less than half of incremental gross profit dollar growth; operating margin grew 260 basis points over FY04 to 15.6%; and earnings per share increased 28% to \$1.52. We continue to benefit from currency trends. We achieved \$71 million of cash flow from operations. In January, our market capitalization crossed the billion dollar threshold, a significant milestone for any company.

Expanding the business—In fiscal 2004 we identified three core competencies—essentially, internal operating strengths that give us a competitive advantage—that we believe can be leveraged to grow our business. While we intend to maintain our market leadership and innovation in the areas of surgical blood salvage and automated blood processing, we are broadening our business development initiatives to target other products and therapeutic classes which will be successfully integrated into the Company. As a result, we've begun to expand our product offerings. We have done this in three ways: through internal R&D, marketing partnerships, and acquisitions. Our product pipeline is beginning to grow, and in fiscal 2006, we are launching four new products that will either offer innovative advances over existing competitive products or create new markets. The market potential of these new products is approximately \$600 million.

	FY04 Guidance	FY04 Results	FY05 Guidance	FY05 Results
Revenue	7–9%	8%	4–6%	5%
EPS	~\$1.13	\$1.19	\$1.43–1.48	\$1.52
Gross margin	44–49%	47.6%	High 40%	51.6%
Operating income growth	+20%	+26%	+20%	+27%
Operating margin	>11.1%	13%	>12.6%	15.6%

- Our plasma disposables revenue declined 15% in the year to \$97 million. Three factors combined to negatively impact plasma revenues. These factors were global industry consolidation; a reduction in plasma collections to compensate for an oversupply of plasma; and the loss of our largest plasma customer when it was acquired by a competitor which subsequently closed the collection centers and repudiated our supply contracts.

This was a challenging year for plasma sales, but the 5% loss to total revenues we experienced because of these plasma market pressures was offset by double-digit revenue gains in other product lines and by currency benefits. Additionally, we focused on controllable areas of plasma sales and secured other sales opportunities in the plasma collection market. We finalized an agreement with ZLB Plasma Services, one of the largest plasma collectors in the world, to be ZLB's exclusive supplier of plasma collection technology in the U.S. This contract will add as much as \$10 million to fiscal 2006 revenues and grow in the years beyond. Finally, we filed an arbitration claim for breach of contract against the competitor who purchased our customer's plasma centers. In May 2005, we were granted an arbitration award of \$27.8 million for our lost profits.


- Our blood bank disposables revenue grew 16% over FY04, to deliver \$130 million in disposables revenue. We are pleased that in a mature market growing only single digits, we were able to grow blood bank revenue beyond market growth for the second consecutive year. Many factors contributed to this result: currency, a shift to our higher priced filtered platelet collection sets in Japan, an increase in revenue from intravenous solutions, unit volume increases in Asia, and market penetration in emerging markets.
- Red cell disposables revenue reached \$29 million, up 29% over FY04. These results were slightly lower than plan, but still show strong growth. We were successful at growing collections at newer accounts. For example, albeit from a small unit base, the American Red Cross grew usage more than 200% over FY04. More than 150,000 units of red cells collected last year by the Red Cross utilized our double red cell collection technology. Additionally, we executed well in our goal to convert customers to filtered disposable sets. By the end of FY05, 43% of total U.S. red cell collections with our collection sets used our filtered disposables, up significantly from 30% in FY04.

Building our business

“This was a challenging year for plasma sales, but the 5% loss to total revenues we experienced because of these plasma market pressures was offset by double digit revenue gains in other product lines and by currency benefits.”

- The OrthoPAT product was the key driver for patient disposables revenue which was \$86 million, up 13% over FY04. OrthoPAT disposables revenue for the year was \$20 million, up 51% over FY04. OrthoPAT revenues benefited from disposables unit growth as well as from price improvement in both the U.S. and Europe. In the U.S., our partner Zimmer Holdings placed more than 500 new machines during the year, positioning us well for continued future growth.
- We developed and gained U.S. and European regulatory approval for the cardioPAT surgical blood salvage system. The cardioPAT system will be marketed in fiscal 2006 for lower blood loss heart surgeries. This is the first internally developed, new Haemonetics device to be brought to market in four years.
- We took an equity stake in and entered into a research collaboration with Arryx Inc., whose proprietary nano-technology uses lasers to separate blood components in the research lab. We are currently reviewing this technology's applications in the blood collection industry. But this research, if proven to be commercially feasible, could also provide us with future opportunities to enter new, adjacent therapeutic markets.
- We welcomed two new Board Members, broadening the areas of expertise on our Board: Susan Bartlett Foote, associate professor and head of the Division of Health Service Research and Policy at the School of Public Health at the University of Minnesota and Pedro Granadillo, recently retired Senior Vice President of Eli Lilly Company with responsibility over global manufacturing and human resources. Each has already made a strong contribution to the Board.

Disposables Revenue Growth
(Dollars in Millions)



Fiscal 2005 was a solid year when measured against our financial and strategic plans. As importantly, it established a foundation and baseline for our high expectations for the future. With the launch of four new products in fiscal 2006, strong market position, and an anticipated rebound in the plasma market, we believe we can now grow revenues faster than we have in the recent past. We will continue to leverage our P&L and expect incremental improvement in gross margin, operating income, and earnings per share.

We thank our employees for their outstanding efforts and the Board of Directors for their significant contributions. In particular, we appreciate the many years of service and counsel of Dr. Harvey Klein and Donna C. E. Williamson, who completed their terms on the Board in fiscal 2005.

Finally, we thank you, our shareholders. Just twenty-four months ago we assumed our new assignments with a promise to create shareholder value and to position your Company for future growth. Our initial efforts are paying off, but we have higher aspirations. We believe the future is bright for Haemonetics, and we're committed to performing to the standards we have set.

Sincerely,

Ronald A. Matricaria
Chairman

Brad Nutter
President and CEO

Building a new product pipeline

expansion

1. Expand the business

We made solid progress in fiscal 2005 on our strategy to expand the business to target other products and therapeutic classes that we can successfully integrate into the Company. Highlights of our success include:

INTERNAL R&D The Donor Division made progress on the Cymbal® device, a next-generation red cell collection device that will have features uniquely suited to a mobile blood collection environment.

The Patient Division obtained U.S. and European clearance to market the cardioPAT surgical blood salvage system in lower blood loss heart surgeries. The device was very well received in customer acceptance trials as we prepare to launch in fiscal 2006.

MARKETING PARTNERSHIPS Haemonetics entered into a marketing partnership under which the Donor Division will sell worldwide the first non-invasive hematocrit testing system. The system will be sold to blood collectors as a replacement to needle stick tests.

The Patient Division extended for another three years its marketing partnership to sell a surgical patient and a blood/fluid warming system in Japan. The partnership was a first step in the Patient Division's mission to move from a surgical blood salvage focus to a broader surgical patient management focus.

ACQUISITIONS Haemonetics took an equity stake in Arryx, Inc. and the Donor Division is collaborating with Arryx on research into using laser nanotechnology to separate blood at the cellular level. While still very much in early stage research, we are excited by the potential for this technology to give us access to new markets.

Haemonetics acquired the Blood Stream family of products which will be launched by the Patient Division over the course of fiscal 2006 and 2007. The first product to be introduced will be a surgical fluid suction device that offers premium suction and can be used with our blood salvage devices. The device can also be used as a stand-alone device for use in any surgery and is our next venture into the broader surgical patient management arena.

Building financial strength

profitability


2. Improve profitability

We also made good progress in fiscal 2005 on improving the profitability of the business. For the second consecutive year we achieved positive drop-through on our P&L. We define positive drop-through as operating income growing faster than gross profit and gross profit growing faster than revenue. This is a discipline that we believe is sustainable year to year and will be a continuing focus in each year of our five-year strategic plan.


Gross margin for the year is a particular success story. Our cost reduction program continues to reduce manufacturing costs, pulling \$5.2 million in costs out of the business this fiscal year. Improved pricing contributed \$1 million to gross profit, and we're making good progress on improving product mix.

We have committed to our shareholders that to maintain this positive drop-through, we will manage expenses to increase no more than half the rate of incremental gross profit dollar growth. In fiscal 2004 and 2005, we managed expenses to 49% and 48% (respectively) of incremental gross profit dollar growth.

Achieving Positive Drop-Through



Gross Margin Continues to Build



Building on governance



Haemonetics' Board of Directors: (from left to right) Brad Nutter, Susan Bartlett Foote, Ronald A. Matricaria (Chairman), Pedro Granadillo, Lawrence Best, Alicia Lopez (Secretary), Yutaka Sakurada, Ronald Gelbman, Benjamin Holmes

The following are examples of Haemonetics' corporate governance principles:

1. Directors

- A majority of directors are independent
- We have three committees: Audit; Compensation and Management Development; and Nominating and Governance
- There are executive sessions of independent directors
- The Board conducts an annual performance review of itself, its committees, and our CEO
- The Board has an active role in our strategy
- Retirement age for directors is 70
- Directors are encouraged to limit directorships
- Conflicts of interest are not allowed
- Our Audit Committee reviews earnings releases, guidance, and some SEC filings
- Our Chairman and CEO positions are separate

2. Compensation

- We require shareholder approval of stock plans
- We will not reprice stock options
- We will not make loans to officers or directors
- We have stock ownership guidelines for directors and senior management

3. General

- We have adopted a code of business conduct
- We have adopted a shareholder rights plan

Sarbanes-Oxley Certifications

Haemonetics has filed with the SEC, as exhibits to its annual report on Form 10-K for the year ended April 2, 2005, the Certifications of the CEO and CFO required under Sections 302 and 906 of the Sarbanes-Oxley Act of 2002.

the Haemonetics Corporation **form 10-k**

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 10-K

**ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the fiscal year ended April 2, 2005.

Commission file number 1-10730

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts

(State of Incorporation)

04-2882273

(I.R.S. Employer Identification No.)

400 Wood Road

Braintree, Massachusetts

(Address of principal executive offices)

02184-9114

(Zip Code)

Registrant's telephone number, including area code: **(781) 848-7100**

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Common stock, \$.01 par value

**Name of each exchange
on which registered**

New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this form 10-K.

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act.) Yes No

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant (assuming for these purposes that all executive officers and Directors are "affiliates" of the Registrant) as of October 2, 2004, the last business day of the registrant's most recently completed second fiscal quarter was \$837,000,000 (based on the closing sale price of the Registrant's Common Stock on that date as reported on the New York Stock Exchange).

The number of shares of the registrant's common stock, \$.01 par value, outstanding as of May 9, 2005 was 33,784,300.

Documents Incorporated By Reference

Portions of the Company's Proxy Statement for the Annual Meeting of Shareholders to be held on July 27, 2005, are incorporated by reference in Part III.

TABLE OF CONTENTS

	<u>Page Number</u>
Item 1. Business.....	3
(a) General History of the Business.....	3
(b) Financial Information about Industry Segments	4
(c) Narrative Description of the Business.....	4
(d) Financial Information about Foreign and Domestic Operations and Export Sales	12
Item 2. Properties.....	13
Item 3. Legal Proceedings	14
Item 4. Submission of Matters to a Vote of Security Holders	14
Item 5. Market For The Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	16
Item 6. Selected Consolidated Financial Data	17
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 7A. Quantitative and Qualitative Disclosures about Market Risk.....	35
Item 8. Financial Statements and Supplementary Data	36
Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure.....	64
Item 9A. Controls and Procedures.....	64
Item 9B. Other Information.....	66
Item 10. Directors and Executive Officers of the Registrant.....	66
(a) Identification of Directors.....	66
(b) Identification of Executive Officers.....	66
(c) Audit Committee Financial Expert	66
Item 11. Executive Compensation.....	66
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.....	66
Item 13. Certain Relationships and Related Transactions	67
Item 14. Principal Accountant Fees and Services.....	67
Item 15. Exhibits and Financial Statement Schedules.....	67
(a) Financial Statement Schedules.....	67
(b) Exhibits.....	67

SIGNATURES

ITEM 1. BUSINESS

(a) General History of the Business

Our Company was founded in 1971 and became publicly owned for the first time in 1979. In 1983, we were acquired by American Hospital Supply Corporation (“AHS”). When Baxter Travenol Laboratories, Inc. acquired AHS in 1985, Baxter divested the Haemonetics business to address antitrust concerns related to the AHS acquisition. As a result, we were purchased in December 1985 by investors that included E. I. du Pont de Nemours and Company (“Du Pont”) and present and former Haemonetics employees. We were incorporated in Massachusetts in 1985. In May 1991, we completed an Initial Public Offering, at which time Du Pont divested its interest.

We are a pioneer and a market leader in developing and manufacturing technology that helps ensure a safe and adequate blood supply and that assists blood banks and hospitals operate efficiently and in compliance with regulatory requirements. To that end, throughout our history, we have been engaged in manufacturing automated systems and single use consumables used in blood donation, blood processing, and surgical salvage of blood. We also develop associated data management technology.

We developed our first automated blood processing system in 1971 and for more than 30 years we have innovated products and services that improve the safety and practice of transfusion medicine. Our direct customers are blood and plasma collectors, hospitals and hospital service providers.

In fiscal year 2004 we embarked upon two strategies: 1) leveraging the core business to improve profitability and 2) expanding the business through internal R&D, marketing partnerships, and acquisition. As a result of strategy 2, we have broadened our core product portfolio to also include complementary products used by our blood collection and hospital customers. Also in fiscal year 2004, we reorganized into two global product families that address our ultimate customer (our customers’ customer): blood donors and surgical patients. Within these product families we offer:

Donor Products

- 1) Our PCS[®] brand systems automate the collection of plasma from donors who are often paid a fee for their donation. The collected plasma is then generally processed into therapeutic pharmaceuticals.
- 2) Blood bank systems:
 - a) Our MCS[®] brand systems automate the collection of platelets from volunteer donors. The systems enable the donation of a larger volume of the donor’s platelets, which are then generally given to cancer patients and others with bleeding disorders.
 - b) Our ACP[®] brand systems automate the process used to freeze, thaw and wash red blood cells. The ACP systems can also be used to wash other cellular parts from red blood cells units before transfusion.
 - c) We also contract manufacture sterile intravenous solutions for pharmaceutical customers. These solutions include generic drugs and other custom drug products.
- 3) Other MCS systems automate the collection of red cells from volunteer donors. These systems maximize the volume of red cells that can be collected from one blood donation, thus helping to alleviate blood shortages. The most predominant product in the red cell product line is our double red cell collection technology which allows for two units of red cells to be collected from one donor. Specialty protocols allowing for the simultaneous collection of a unit of red cells and a unit of plasma or a unit of red cells and a unit of platelets are also available in various parts of the world.

Patient Products

- 1) Surgical blood salvage systems, used during and after surgery to collect a patient’s own blood for reinfusion, including:
 - a) Our Cell Saver[®] brand systems for higher blood loss surgeries and trauma, and

- b) Our OrthoPAT[®] brand systems for lower, slower blood loss procedures, typically orthopedic surgeries.
- c) Our cardioPAT[™] brand system for blood loss during and after beating heart surgeries or for blood loss after various coronary artery bypass graft (“CABG”) surgeries. The cardioPAT is our newest blood salvage system. The cardioPAT system entered limited market release in April 2005.

Our principal operations are in the U.S., Europe, and Japan and other parts of Asia. Our products are marketed in more than 50 countries around the world via a direct sales force as well as some independent distributors and agents.

In fiscal year 2005, we remained focused on increasing sales of our newer red cell collection technology and orthopedic surgical blood salvage system. In addition to these existing product lines, however, we also prepared to expand the business by completing our Core Competency Review Process which was initiated in fiscal year 2004. The objective of the Core Competency Review was to determine what competencies we uniquely possess that can be leveraged to grow our business. We identified three: superior service, manufacturing process management, and innovation. Finally, in fiscal year 2005, we focused resources on five new products for introduction in fiscal year 2006.

(b) Financial Information about Industry Segments

Although we address our customer constituents through two global product families (Donor and Patient), we manage our business as one operating segment: automated blood processing systems. Our chief operating decision maker uses consolidated financial results to make operating and strategic decisions. Manufacturing processes, as well as the regulatory environment in which we operate, are largely the same for all product lines.

The financial information required for the business segment is included herein in Note 16 of the financial statements, entitled SEGMENT, GEOGRAPHIC AND CUSTOMER INFORMATION.

(c) Narrative Description of the Business

(i) Products

We develop and market a variety of automated systems for blood donors and patients world wide that collect, process, and surgically salvage their blood. We also market data management systems through our subsidiary, Fifth Dimension Information Systems (“Fifth Dimension”) to promote efficient and compliant operations of blood collectors, principally plasma collectors.

All of our blood systems involve the extracorporeal processing of human blood, which is made up of components called red blood cells, plasma, platelets, and white blood cells. Doctors today generally treat patients with a transfusion of only the blood component needed, rather than with whole blood. The different components have different clinical applications. For example, plasma derived products treat a variety of illnesses and hereditary disorders such as hemophilia; red cells treat trauma patients or patients undergoing major surgeries involving high blood loss such as open heart surgery or organ transplant, and platelets treat cancer patients undergoing chemotherapy.

With our automated blood collection systems, a blood donation can be targeted to the specific blood component needed by a blood collector. More of that blood component can be collected during any one donation event because the blood component not targeted is returned to the donor through a sterile, closed-circuit disposable set used for the blood donation procedure.

With our automated blood processing systems, blood collectors and hospitals can freeze and thaw red cells so that they can maintain a frozen blood reserve. Blood reserves are often maintained to adequately respond to large-scale emergencies in which many people require blood transfusions or to treat patients who require transfusions of very rare blood. Our blood processing systems can also remove the plasma from red cells for patients who need specially treated blood.

With our surgical blood salvage systems, medical teams can collect blood lost by a surgical patient during or after the surgery, clean it, and make it available for transfusion back to the patient. These systems ensure that elective surgery will not be cancelled due to lack of available blood, and that a patient receives the safest blood possible – his or her own.

In every one of our major product offerings: plasma collection, platelet collection, red cell collection, cell processing and surgical cell salvage, we invented the technology that first created the market. We continue to innovate our product offerings with next generation technologies.

Automated Plasma Collection and Data Management Systems

Automated plasma collection technology allows for the safe and efficient collection of plasma from donors who are usually paid a fee for their blood donation. The plasma which is collected is then further processed (“fractionated”) by pharmaceutical companies into therapeutic and diagnostic products that aid in the treatment of: immune diseases, inherited coagulation disorders (e.g., hemophilia) and blood volume loss (e.g. from trauma). The collected plasma is also used in the manufacture of vaccines and blood testing and quality control reagents. Our role in the plasma industry is limited to the supply of plasma collection and data management systems to plasma collectors. Our business does not include the actual collection, fractionation, or distribution of plasma-derived pharmaceuticals, businesses mostly conducted by large multi-national pharmaceutical corporations.

Until automated plasma collection technology was pioneered and introduced by our Company in the 1980s, plasma for fractionation was collected manually. Manual collection was time-consuming, labor-intensive, produced relatively poor yields, and posed risk to donors. Currently the vast majority of plasma collections worldwide are performed using automated collection technology because it is safe and cost-effective. We market our PCS2 automated plasma collection systems to commercial plasma collectors as well as not-for-profit blood banks and government affiliated plasma collectors worldwide.

We offer “one stop shopping” to our plasma collection customers, enabling them to source from us the full range of products necessary for their plasma collection operations. To that end, in addition to providing plasma collection equipment and disposables, we offer plasma collection containers, intravenous solutions necessary for plasma collection and storage, and data management technology to automate plasma collectors’ operations. Data management is supplied through our subsidiary, Fifth Dimension, a leading provider of information management products and services for plasma collectors and fractionators. A majority of plasma collectors currently use manual systems to track their donors and collected plasma. Fifth Dimension’s sales are recorded in the miscellaneous and service revenue line, although the majority of its sales currently are to plasma collectors. Our strategy is to expand Fifth Dimension’s sales to not-for-profit blood collectors. We made initial headway into this strategy in late fiscal year 2005 with an agreement to support the U.S. Department of Defense’s Blood Management Software System.

Blood Bank Systems

The Blood Collection Market for Transfusion

There are millions of blood donations throughout the world every year to obtain blood products for transfusion to surgical, trauma, or chronically ill patients. In the U.S. alone approximately 14 million units of blood are collected each year.

Patients requiring blood are rarely transfused with whole blood. Instead, a patient typically receives only the blood component necessary to treat their clinical condition: red cells to surgical or trauma patients, platelets to surgical or cancer patients, and plasma to surgical patients.

Worldwide demand for blood continues to rise as the population ages and more patients have need for and access to medical therapies that require blood transfusions. At the same time, tighter donor eligibility requirements to improve blood safety have decreased the number of donors willing or able to donate blood. Thus, this worldwide market is growing modestly in the low single digits.

Most donations worldwide are non-automated procedures (also referred to as “manual donations”). In a manual donation, a person donates about a pint of whole blood, bleeding by gravity directly into a blood collection bag. After the donation, a laboratory worker manually processes the blood and separates it into its constituent parts: red cells, platelets and plasma. One pint of whole blood contains one transfusable dose of red cells, one-half to one transfusable dose of plasma, and one-fifth to one-eighth transfusable dose of platelets.

We do not sell blood collection disposables for the large, non-automated part of the blood collection market for transfusions. Abbott Laboratories, Baxter International, Pall Corporation, Terumo and others supply this market with whole blood collection supplies such as needles, plastic blood bags, solutions and tubing.

In contrast to manual collections, automated procedures eliminate the need to manually separate whole blood at a remote laboratory. Instead the blood separation process is automated and occurs “real-time” while the blood donor is attached to the blood collection system. In this separation method, only the specific blood component targeted is collected, and the remaining components are returned to the blood donor. Among other things, automated blood collection allows significantly more of the targeted blood component to be collected during a donation event.

Today in the U.S., automated collection systems are used annually to collect more than 550,000 red cell units and about 1.5 million platelet units (called “single donor” platelets.) One donation from a single donor can produce enough platelets for a transfusable dose as compared to a pooled platelet that combines platelet fractions from 5-8 different whole blood donors).

Our products currently address the small part of the blood collection market that uses automation to enhance blood collection safety and efficiency, as well as regulatory compliance. Though we compete against large companies including Baxter International and Gambro BCT, we are the only company whose business is predominantly focused on automated blood collection.

Automated Platelet Collection Systems

Automated platelet collection systems collect one or more therapeutic “doses” of platelets during a single donation by a volunteer blood donor. Platelets derived from non-automated donations of whole blood (also called manual collections) must be “pooled” together with platelets from 5 to 8 other manual donations to make a single therapeutically useful dose because platelets are only a very small portion of whole blood volume. We invented the automation of platelet collection, resulting in improved platelet yields and improved patient safety.

Platelet therapy is frequently used to alleviate the side effects of bone marrow suppression, a condition in which bone marrow is unable to produce a sufficient quantity of platelets. Bone marrow suppression is most commonly a side effect of chemotherapy. Physicians who prescribe platelet therapy have increasingly turned to “single donor” platelet products (i.e., enough platelets collected from a single donor, during an automated collection procedure, to constitute a transfusable dose) to minimize a patient’s exposure to multiple donors and possible blood-borne diseases.

Related products that improve safety of platelets

Bacterial Detection

Over the past two years, bacterial detection of platelets has become an important trend in the transfusion industry. To reduce risks to patients receiving transfusions, the U.S. has implemented requirements that all platelets be tested for bacteria and several European blood collection agencies are evaluating bacterial screening. Bacterial contamination is one of the most common causes of transfusion-related death, but it also has other risks which can result in longer hospitalization. In February 2004, we reached an agreement with Hemosystem SA to market its bacterial screening technology, Scansystem[®] in Europe, the Middle East, Africa, and Latin America for the next three years. As part of the agreement, we also assumed right of first refusal to market the product in major Asian countries. Local European evaluations of Scansystem are ongoing. Additionally, in the fourth quarter of fiscal year 2004, we announced U.S. regulatory clearances for two blood sampling systems. The systems are specifically designed to facilitate the collection of a sample of platelets for the bacterial detection test. One system is integrated into our platelet collection disposable kit and the other system can be used to sample platelets collected through any other means.

Pathogen Reduction

Pathogen reduction technologies are processes to eliminate or reduce pathogens, including viruses and bacteria, from blood prior to its transfusion to patients. Pathogen reduction has been discussed by the transfusion community for many years, and is in various stages of development and/or commercialization by several companies, not including Haemonetics. In December 2001 we entered into an agreement with Baxter International, Inc. (“Baxter”) to enable us to seamlessly integrate our platelet collection systems with InterSOL which is a platelet storage solution for use with the INTERCEPT[®] Platelet System for pathogen reduction of platelets. To date, pathogen reduction of platelets is not routinely practiced in most countries. However, because of our agreement with Baxter we are poised to participate in this market should there be a trend toward pathogen reduction.

Automated Blood Cell Processing Systems

Our cell processing business is based on technology that enables users to add and remove solutions or other substances to and from blood components. We have several technologies that support this business.

The most significant technology allows the freezing and thawing of blood to enable blood banks to better manage their red cell inventory. Although it has been possible for many years to freeze red cells for up to ten years, the freezing and thawing processes took place in a manual, open-circuit system, which exposed red cells to the potential for bacterial contamination. Once the cells were thawed, they had to be transfused within 24 hours. The ACP215 automated cell processing system extends thawed cells' shelf life to 14 days by performing the freezing and thawing processes in an automated, closed-circuit technology.

Automated Red Cell Collection Systems

See the section above entitled "Blood Bank Systems: Blood Collection for Transfusion" to learn about the market for our red cell collection systems.

Automated red cell collection, a market we created, allows for the safe and efficient collection of more red cells from a single blood donor than from manual, whole blood collections. Most red cells are derived from manual collection of whole blood, after which the components are separated. However, this manual procedure involves time-consuming, error-prone secondary handling and processing in a laboratory that tax a blood collector's limited resources. Red cell shortages are a common problem plaguing many healthcare systems worldwide, particularly the U.S.

Our MCS brand systems help blood collectors address their operational challenges. The system automates the blood separation function, eliminating the need for laboratory processing and enables the collection of two transfusable doses of red cells from a single donor thus alleviating blood shortages. We call this our two unit protocol or double red cell collection.

In addition to the two unit protocol, blood collectors can use the MCS brand system to collect either one unit of red cells and a "jumbo" (double) unit of plasma or one unit of red cells and one unit of platelets from a single donor or they may leukoreduce their two unit red cell collections. Leukoreduction is the removal of potentially harmful white blood cells from the blood. Leukoreduction has been adopted in many countries worldwide, and an estimated 80% of all red cells in the U.S. are now leukoreduced.

During fiscal year 2005, blood shortages continued and blood banks continued their adoption of double red cell collection. United Blood Services, the second largest collector of blood in the U.S., expanded its automated red cell program to include our leukoreduction red cell collection kit. Throughout the year, the American Red Cross also expanded its use of our technology. The American Red Cross finished the fiscal year collecting approximately 3% of its red cell units on our technology.

Since fiscal year 2003, we directed research and development resources to our next generation automated red cell collector, called the Cymbal device (formerly known as the Red Cell Collector). The Cymbal system is an automated device to collect and process two units of red cells from donors which is smaller, lighter and more portable than our current red cell collection technology. We continued to advance the Cymbal system in fiscal year 2005. We expect CE marking of this device during fiscal year 2006.

See the section entitled "Research and Development" for further discussion.

Surgical Blood Salvage Systems

Surgical blood salvage, also known as autotransfusion, involves the collection of a patient's own blood during and after surgery, for reinfusion to that patient. In surgical blood salvage, blood is suctioned from a wound site, collected in a centrifuge, and cleaned and filtered to remove unwanted substances from the recovered blood. The blood is transferred to a collection bag and made available for transfusion back to the patient. This process occurs in a sterile, closed-circuit; consumable set which sits inside our device. We market our surgical blood salvage products to hospital-based medical specialists, primarily cardiovascular, orthopedic, and trauma surgeons or to surgical suite service providers.

Loss of blood is common in open heart, trauma, transplant, vascular, and orthopedic procedures, and the need for transfusion of oxygen-carrying red cells to make up for lost blood volume is routine. Prior to the introduction of our technology, patients were transfused exclusively with blood from volunteer donors. Donor blood carries various potential risks including (i) risk of transfusion with the wrong blood type (the most common cause of transfusion-related death), (ii) risk of transfusion reactions including death, but more commonly chills, fevers or other side effects that can prolong a patient's recovery, and (iii) risk of transfusion of blood with a blood-borne disease or infectious agent.

As a result of numerous blood safety initiatives, today's blood transfusions are extremely safe, especially in well developed and resourced health care systems. However, transfusions are not risk free. Surgical blood salvage reduces or eliminates a patient's dependence on blood donated from others and ensures that the patient receives the safest blood possible – his or her own.

Surgical blood salvage is also a cost effective alternative for hospitals compared to the total cost of transfusing donor blood. Blood shortages have also reinforced the benefits of surgical blood salvage. As hospitals are forced to consider canceling elective surgeries due to unavailability of blood, they can turn to surgical blood salvage as a means of conserving their blood supply for other patients.

We pioneered the first surgical blood salvage systems. Today, we market the Cell Saver brand system which is targeted to procedures that involve rapid, high volume blood loss such as cardiovascular surgeries, as well as the OrthoPAT system which is targeted to orthopedic procedures that involve slower, lower volume blood loss that often occurs well after surgery. We are currently in the early stages of introducing the cardioPAT system for use in open heart surgeries when there is less blood loss.

In fiscal year 2003, we announced a marketing agreement with Augustine Medical Corporation International (a subsidiary of Arizant, Inc.) under which we now market the Bair Hugger[®] surgical patient warming system in Japan. The Bair Hugger system is a device and disposable blanket that warms a patient before, during, and after surgery so that the patient's body temperature remains stable. Published clinical studies demonstrate that maintaining normal body temperatures during surgery can reduce the incidence of wound infection, bleeding, cardiac events, and mortality. In fiscal year 2005, we renegotiated this contract, extending it another three years and adding marketing of the Ranger[®] product in Japan. The Ranger product is a fluid warming system for surgical patients.

(ii) Revenue Detail

We discuss our revenues using the following categories:

Disposables (the consumables used in blood collecting, processing, and salvaging and fees for the use of our equipment.) Equipment (the sale of devices) Miscellaneous and Service (including Fifth Dimension software management systems and service contracts)

In fiscal year 2005, sales of disposable products accounted for approximately 89.3% of net revenues. Sales of our disposable products were 5.3% higher in 2005 than in 2004 and grew at a compound average annual growth rate of 5.7% for the three years ended April 2 2005. The favorable effects of foreign exchange contributed 5.0% of the 5.3% increase in net sales during fiscal year 2005 with the remaining 0.3% increase resulting from increases in disposable revenues across our blood bank, red cell and surgical and product lines due to unit increases and product mix shifts. These increases were almost entirely offset by decreases in our plasma product line. Sales of equipment accounted for approximately 5.4% of net revenues in fiscal year 2005 and approximately 4.6% in fiscal year 2004. The increase in equipment revenue during fiscal year 2005 is largely attributable to the sale of MCS+ red cell collection devices to the American Red Cross in the first quarter of fiscal year 2005).

Service and other miscellaneous revenues accounted for approximately 5.3% and 6.0% of net revenues in fiscal year 2005 and fiscal year 2004, respectively. The decrease during fiscal year 2005 was due to reduced software revenue from Fifth Dimension. Fifth Dimension currently sells its products primarily to plasma customers who have been

negatively impacted by the recent volatility and consolidation in the worldwide commercial plasma collection market.

(iii) Marketing/Sales/Distribution

We market and sell our products to hospitals and hospital service providers, blood systems and independent blood banks, commercial plasma collection centers, and national health organizations through our own direct sales force (including full-time sales representatives and clinical specialists) as well as independent distributors. Sales representatives target the primary decision-makers within each of those organizations.

In fiscal year 2005, for the fifth consecutive year, we received the Omega NorthFace ScoreBoard Award for exemplary service to customers. This award is presented to the highest-ranked organizations based on customer ratings of firms' actual performance against customer expectations in areas such as phone support, on-site operations, technical services, and training.

(iv) United States

In fiscal year 2005, approximately 34.3% of consolidated net sales were generated in the U.S. where we use a direct sales force to sell the majority of our products. We have an exclusive distribution agreement with Zimmer Holdings Inc. for the sale and marketing of the OrthoPAT system within the U.S.

(v) Outside the United States

In fiscal year 2005, approximately 65.7% of consolidated net revenues were generated through sales to non-U.S. customers. Our direct sales force in Europe and Asia includes full-time sales representatives and clinical specialists based in the United Kingdom, Germany, France, Sweden, the Netherlands, Italy, Austria, Hong Kong, Canada, Japan, Switzerland, Czech Republic, China, Taiwan, and Belgium. We also use various distributors to market our products in South America, the Middle East, and parts of Europe and the Far East.

(vi) Research and Development

We operate research and development ("R&D") centers in Switzerland, Japan, and the United States, so that protocol variations are incorporated to closely match local customer requirements. In addition to the above R&D facilities, our Fifth Dimension subsidiary maintains development operations in Edmonton, Alberta, Canada.

Customer collaboration is also an important part of our technical strength and competitive advantage. We have built consulting relationships with a significant number of transfusion experts around the world. These individuals provide us with ideas for new products and applications, enhanced protocols, and potential test sites as well as objective evaluations and expert opinions regarding technical and performance issues.

The development of extracorporeal blood processing systems has required us to maintain technical expertise in various engineering disciplines, including mechanical, electrical, software, biomedical, and materials. Innovations resulting from these various engineering efforts enable us to develop systems that are faster, smaller, and more user-friendly, or that incorporate additional features important to our customer base.

Our expenditures for R&D were \$20.0 million for fiscal year 2005(5.2% of sales), \$17.4 million for fiscal year 2004(4.8% of sales) and \$19.5 million (5.8% of sales) for fiscal year 2003. All R&D costs are expensed as incurred. We expect to continue to invest resources in R&D.

In fiscal year 2005, R&D resources were allocated to completing work on a new surgical blood salvage device, the cardioPAT, enhancements to the MCS platelet collection platform, the Cymbal (formerly Red Cell Collector), two blood collection software systems - E*Interview and HaemoConnect, as well as several projects to enhance our current product portfolio. The cardioPAT surgical blood salvage system is a small, portable, and operator-friendly surgical blood salvage device designed to address lower volume blood loss during and after open heart surgery. This device entered limited market release in early fiscal year 2006. Our new MCS platelet collection protocol adds several new enhancements in response to customer feedback. This device entered clinical trials at the end of fiscal year 2005.

(vii) Manufacturing

Our principal manufacturing operations (equipment, disposables, and solutions) are located in Braintree, Massachusetts; Leetsdale, Pennsylvania; Union, South Carolina; and Bothwell, Scotland.

In general, our production activities occur in a controlled setting or “cleanroom” environment. Each step of the manufacturing and assembly process is quality checked, qualified, and validated. Critical process steps and materials are documented to ensure that every unit is produced consistently and meets performance requirements.

Some component manufacturing is performed by outside contractors according to our specifications. We maintain important relationships with two Japanese manufacturers that provide finished consumables in Singapore, Japan, and Thailand. Certain parts and components are purchased from various single sources. If necessary, we believe that, in most cases, alternative sources of supply could be identified and developed within a relatively short period of time. Nevertheless, an interruption in supply could temporarily interfere with production schedules and affect our operations. All of our equipment and disposable manufacturing sites are certified to the ISO 13485 standard and to the Medical Device Directive allowing placement of the CE mark of conformity.

Each blood processing machine is designed in-house and assembled from components that are either manufactured by us or by others to our specifications. The completed instruments are programmed, calibrated, and tested to ensure compliance with our engineering and quality assurance specifications. Inspection checks are conducted throughout the manufacturing process to verify proper assembly and functionality. When mechanical and electronic components are sourced from outside vendors, those vendors must meet detailed qualification and process control requirements. During fiscal year 2005, we manufactured approximately 83% of our equipment. The remainder was manufactured for us by outside contractors.

We have established a Customer Oriented Redesign for Excellence (“CORE”) program, which is based on the tenets of Total Quality of Management (“TQM”) and using Six Sigma Statistic methods. This program’s goals include: 1) improving customer satisfaction through top quality and on-time deliveries, 2) lowering production costs, and 3) optimizing inventories.

(viii) Intellectual Property

We hold patents in the United States and many international jurisdictions on some of our machines, processes, disposables and related technologies. These patents cover certain elements of our systems, including protocols employed in our equipment and certain aspects of our processing chambers and disposables. Our patents may cover current products or may be defensive in that they are directed to technologies not yet embodied in our current products. We also license patent rights from third parties that cover technologies that we use or plan to use in our business. We consider our patent rights to be important to our business. To maintain our competitive position, we rely on the technical expertise and know-how of our personnel and on our patent rights. We pursue an active and formal program of invention disclosure and patent application in both the United States and international jurisdictions. We own various trademarks that have been registered in the United States and certain other countries.

Our policy is to obtain patent and trademark rights in the U.S. and foreign countries where such rights are available and we believe it is commercially advantageous to do so. However, the standards for international protection of intellectual property vary widely. We cannot assure that pending patent and trademark applications will result in issued patents and trademarks, that patents issued to or licensed by us will not be challenged or circumvented by competitors, or that our patents will not be found to be invalid.

(ix) Competition

We created our markets and have established a record of innovation and market leadership in each of the areas in which we compete. Although we compete directly with others, no one company competes with us across the full line of products.

In order to remain competitive, we must continue to develop and acquire cost-effective new products, technologies and services. We believe that our ability to maintain a competitive advantage will continue to depend on a combination of factors, including factors within our control (reputation, regulatory approvals, patents, unpatented proprietary know-how in several technological areas, product quality, safety and cost effectiveness and continual and rigorous documentation of clinical performance) as well as factors outside of our control (regulatory standards, medical standards and the practice of medicine).

We innovated the plasma collection market. Prior to our invention of the PCS system, plasma was collected manually, posing significant risks to donors. In the automated plasma collection markets, we compete with Baxter International, Inc. on the basis of quality, ease of use, services and technical features of systems, and on the long-term cost-effectiveness of equipment and disposables. To a much lesser degree, our automated systems also compete with manual collection systems, which are less expensive, but are also slower, less efficient, and clinically riskier. Baxter has pursued a strategy of developing plasma collection sites and acquiring collection centers, which has altered the competitive landscape and affected our sales. In October 2003, Baxter acquired our largest U.S. plasma customer, Alpha Therapeutic Corporation (“Alpha”). Upon Baxter’s announcement of its acquisition of Alpha’s business, Baxter closed 38 of 41 of the former Alpha centers and sold the remaining three centers. (These three centers remain Haemonetics’ customers.) While Baxter has closed some of its plasma collection centers, there can be no assurance that it will not acquire other plasma collection centers, some of which may currently use our collection technology.

In the automated platelet collection markets, competition is based on continual performance improvement, as measured by the time and efficiency of component collection and the quality of the components collected. Our quality is exceptional, as evidenced by more than 70% market share in Japan, where quality is a leading purchasing consideration. Our major competitors in the automated platelet collection market are Gambro BCT, Inc. and Baxter. Each of these companies has taken a different technological approach in designing their systems for the automated platelet collection market. In the platelet collection market, we also compete with whole blood collections from which pooled platelets are derived.

In the cell processing market, competition is based on level of automation, labor-intensiveness, and system type (open versus closed). Open systems are weaker in GMP compliance and blood processed through them has a 24 hour shelf life. We do have open system cell processors which compete with Gambro BCT systems. Our closed system cell processor gives blood processed through it a 14 day shelf life and has no competition.

Our most recent innovation is automated red cell collection which we pioneered in the late 1990s. We preceded one competitor, Gambro BCT, Inc. to market by 2 years, and the other competitor, Baxter, to market by six years. However, it is important to note that currently less than 1% of the forty million red cells collected worldwide and about 4% of the fourteen million red cells collected in the U.S. annually are collected via automation. So, we more often compete with traditional (manual) methods of deriving red cells by collecting and separating a pint of whole blood on the basis of total cost, process control, product quality, and inventory management.

We invented surgical blood salvage, and the Cell Saver brand is recognized worldwide. In this high blood loss surgical market, competition is based on reliability, ease of use, service, support, and price. Each manufacturer’s technology is similar, and we compete principally with Medtronic, Fresenius, and Sorin Biomedica.

In the orthopedic surgical blood salvage market there are no direct competitors. The OrthoPAT system is the only system designed specifically for use in these surgeries where a patient often bleeds more slowly, bleeds less, and bleeds well after surgery.

Our technical staff is highly skilled, but many competitors have substantially greater financial resources and larger technical staffs at their disposal. There can be no assurance that such competitors will not direct substantial efforts and resources toward the development and marketing of products competitive with those of Haemonetics.

(x) Seasonality

Net revenues have historically been higher in the second half of our fiscal year, reflecting principally the seasonal buying patterns of our customers. This has proven true in four of our last five fiscal years with the exception being fiscal year 2003 where the second half of our fiscal year had slightly lower revenues due principally to market conditions in plasma.

(xi) Government Regulation

The products we manufacture and market are subject to regulation by the Center of Biologics Evaluation and Research (“CBER”) and the Center of Devices and Radiological Health (“CDRH”) of the United States Food and Drug Administration (“FDA”), and other non-United States regulatory bodies.

All medical devices introduced to the United States market since 1976 are required by the FDA, as a condition of marketing, to secure either a 510(k) pre-market notification clearance or an approved Pre-market Approval Application (“PMA”). In the United States, software used to automate blood center operations and blood collections and to track those components through the system are considered by FDA to be medical devices, subject to 510(k) pre-market notification. Intravenous (“IV”) solutions marketed by us for use with our automated systems (blood anticoagulants and solutions for storage of red blood cells) require us to obtain from CBER an approved New Drug Application (“NDA”) or Abbreviated New Drug Application (“ANDA”). A 510(k) pre-market clearance indicates FDA’s agreement with an applicant’s determination that the product for which clearance is sought is substantially equivalent to another legally marketed medical device. The process of obtaining a 510(k) clearance may take up to 24 months and involves the submission of clinical data and supporting information. The process of obtaining NDA approval for solutions is likely to take much longer than 510(k) approvals because the FDA review process is more complicated.

We maintain customer complaint files, record all lot numbers of disposable products, and conduct periodic audits to assure compliance with FDA regulations. We place special emphasis on customer training and advise all customers that blood processing procedures should be undertaken only by qualified personnel.

We are also subject to regulation in the countries outside the United States in which we market our products. Many of the regulations applicable to our products in such countries are similar to those of the FDA. However, the national health or social security organizations of certain countries require our products to be qualified by those countries before they can be marketed in those countries. We have complied with these regulations and have obtained such qualifications.

Federal, state and foreign regulations regarding the manufacture and sale of products such as ours are subject to change. We cannot predict what impact, if any, such changes might have on our business.

(xii) Environmental Matters

We do not anticipate that compliance with federal, state, and local environmental protection laws presently in effect will have a material adverse impact upon our business or will require any material capital expenditures. However, environmental laws, including those that regulate raw materials for medical grade plastics, are subject to change. We cannot predict what impact, if any, such changes might have on our business.

(xiii) Employees

As of April 2, 2005, we employed 1,546 persons assigned to the following functional areas: manufacturing, 791; sales and marketing, 226; general and administrative, 202; research and development, 138; and quality control and field service, 189. We consider our employee relations to be satisfactory.

(xiv) Availability of Reports and Other Information

All of our corporate governance materials, including the Principles of Corporate Governance, the Business Conduct Policy and the charters of the Audit, Compensation, and Nominating and Governance Committees are published on the Investor Relations section of our website at http://www.haemonetics.com/site/content/investor/corp_gov.asp. Such information is also available in print to any shareholder who requests it. All requests should be directed to our Company’s Secretary. On this web site the public can also access, free of charge, our annual, quarterly and current reports and other documents filed or furnished to the Securities and Exchange Commission as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.

(d) Financial Information about Foreign and Domestic Operations and Export Sales

The financial information required by this item is included herein in Note 16 of the financial statements, entitled *Segment, Geographic and Customer Information*. Sales to the Japanese Red Cross accounted for 23.7% of net

revenues in fiscal year 2005. No other customer accounted for more than 10% of our net revenues. For more information concerning significant customers, see subheading of Note 2 of the financial statements, entitled, Concentration of Credit Risk and Significant Customers.

Cautionary Statement

Statements contained in this report, as well as oral statements we make which are prefaced with the words “may,” “will,” “expect,” “anticipate,” “continue,” “estimate,” “project,” “intend,” “designed,” and similar expressions, are intended to identify forward looking statements regarding events, conditions, and financial trends that may affect our future plans of operations, business strategy, results of operations, and financial position. These statements are based on our current expectations and estimates as to prospective events and circumstances about which we can give no firm assurance. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made. As it is not possible to predict every new factor that may emerge, forward-looking statements should not be relied upon as a prediction of our actual future financial condition or results. These forward-looking statements, like any forward-looking statements, involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. Such risks and uncertainties include technological advances in the medical field and our standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand and market acceptance of our products, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, foreign currency exchange rates, changes in customers’ ordering patterns, the effect of industry consolidation especially as seen in the Plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate. The foregoing list should not be construed as exhaustive.

ITEM 2. PROPERTIES

Our main facility is located on 14 acres in Braintree, Massachusetts. This facility is located in a light industrial park and was constructed in the 1970s. The building is approximately 180,000 square feet, of which 70,000 square feet is devoted to manufacturing and quality control operations, 35,000 square feet to warehousing, 68,000 square feet to administrative and research and development activities and 7,000 square feet is available for expansion. See Note 7 to the financial statements for details of our mortgage on the Braintree facility.

On property adjacent to the Braintree facility we lease 43,708 of additional office space. This facility is used for sales, marketing, finance and other administrative services. Annual lease expense for this facility is \$591,842.

We lease an 81,850 square foot facility in Leetsdale, Pennsylvania. This facility is used for warehousing, distribution and manufacturing operations. Annual lease expense is \$311,330 for this facility.

We own a facility in Bothwell, Scotland used to manufacture disposable components for European customers. The original facility is approximately 22,200 square feet. An addition of 18,000 square feet is currently under construction with occupancy planned for early fiscal year 2006. This expansion will provide 10,000 square feet of warehouse space replacing space currently leased for this purpose.

We own a facility in Union, South Carolina. This facility is used for the manufacture of sterile solutions to support our blood bank (component therapy) and plasma businesses. Additionally, this facility is engaged in contract manufacturing of other sterile solutions for veterinary and pharmaceutical customers. The facility is approximately 69,300 square feet.

We also lease a 61,000 square foot facility in Avon, Massachusetts. This facility is used for warehousing and distribution of products. Annual lease expense for this facility is \$370,671.

Fifth Dimension, which develops and markets software for the blood bank and plasma business, leases 13,799 square feet of office space in Edmonton, Alberta, Canada. Annual lease expense if \$161,906.

We also lease sales, service, and distribution facilities in Japan, Europe (Austria, Belgium, Czech Republic, France, Germany, Italy, Sweden, Switzerland, the Netherlands, and United Kingdom), China, Hong Kong and Taiwan to support our international business.

ITEM 3. LEGAL PROCEEDINGS

We are presently engaged in various legal actions, and although our ultimate liability cannot be determined at the present time, we believe that any such liability will not materially affect our consolidated financial position or our results of operations.

Our products are relied upon by medical personnel in connection with the treatment of patients and the collection of blood from donors. In the event that patients or donors sustain injury or death in connection with their condition or treatment, we, along with others, may be sued, and whether or not we are ultimately determined to be liable, we may incur significant legal expenses. In addition, such litigation could damage our reputation and, therefore, impair our ability to market our products or to obtain professional or product liability insurance or cause the premiums for such insurances to increase. We carry product liability coverage. While we believe that the aggregate current coverage is sufficient, there can be no assurance that such coverage will be adequate to cover liabilities which may be incurred. Moreover, we may in the future be unable to obtain product and professional liability coverages in amounts and on terms that we find acceptable, if at all.

In order to aggressively protect our intellectual property throughout the world, we have a program of patent disclosures and filings in markets where we conduct significant business. While we believe this program is reasonable and adequate, the risk of loss is inherent in litigation as different legal systems offer different levels of protection to intellectual property, and it is still possible that even patented technologies may not be protected absolutely from infringement.

On January 21, 2004, we filed a claim for binding arbitration against Baxter, seeking an arbitration award that compels Baxter to honor numerous supply contracts it assumed when Baxter purchased the plasma collection operations of Alpha Therapeutic Corporation, our largest plasma customer, or to pay us damages. The matter was tried before an arbitration panel for three weeks ending April 1, 2005. The arbitration panel issued its decision on May 20, 2005 and awarded the Company \$27.8 million in damages plus legal costs

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

Executive Officers of the Registrant

The information concerning our Executive Officers is as follows. Executive officers are elected by and serve at the discretion of our Board of Directors.

PETER ALLEN joined our Company in 2003 as President, Donor Division. Prior to joining our Company, Mr. Allen was Vice President of The Athena Group, a private equity firm providing services to the global healthcare industry. From 1998 to 2001, he held various positions including Vice President of Sales and the Oncology Business at Syncor International, a provider of radiopharmaceutical and comprehensive medical imaging services. Previously, he held executive level positions in sales, marketing and operations in DataMedic, Inc., Enterprise Systems, Inc./HBOC, and Robertson Lowstuter, Inc. Mr. Allen has also worked in sales at American Hospital Supply Corporation and Baxter International, Inc.

BRIAN CONCANNON joined our Company in 2003 as President, Patient Division. Prior to joining our Company, Mr. Concannon was President, Northeast Region, Cardinal Health Medical Products and Services. From 1996 to 1999, he was with Allegiance Healthcare, most recently holding the position of Vice President, Distribution Sales and Operations. Mr. Concannon has also held various sales and marketing positions at American Hospital Supply Corporation and Baxter Healthcare Corporation.

ROBERT EBBELING joined our Company in 1987 as Manager of Injection Molding. Throughout his career at our Company, Mr. Ebbeling has held various management and executive positions in manufacturing and operations. In 1996, he was appointed to Senior Vice President, Manufacturing. In February 2003, Mr. Ebbeling was promoted to Executive Vice President, Manufacturing, and then in August 2003, he was promoted to Vice President, Operations. Prior to joining our Company, Mr. Ebbeling was Vice President, Manufacturing, for Data Packaging Corporation.

DR. ULRICH ECKERT joined our Company in 1995 as Vice President, Haemonetics Germany. In 1998 and 2001, Dr. Eckert assumed additional responsibility for European plasma marketing and our Nordic countries' subsidiaries respectively. In 2002, he was promoted to President, Europe and Latin America. Prior to joining our Company, Dr. Eckert spent eight years with Apple Computer where his most recent responsibility was Director, Business Systems for Germany, Austria and Switzerland.

ALICIA R. LOPEZ joined our Company in 1988 as General Counsel and Director of Human Resources. Throughout her career at Haemonetics, Ms. Lopez has held various executive positions with responsibilities over legal, human resources, administration, regulatory affairs, and investor relations. Since 1990, she has served as Secretary to the Board of Directors. In 2000, Ms. Lopez was appointed Senior Vice President. In 2003, Ms. Lopez was named Vice President and General Counsel and in 2004 she was promoted to General Counsel and Vice President of Administration. Prior to joining our Company, Ms. Lopez was a litigation associate with the law firm of Sullivan & Worcester.

BRAD NUTTER joined our Company in 2003 as Board Member, President and Chief Executive Officer. Prior to joining our Company, Mr. Nutter was President and Chief Executive Officer of Gambro Healthcare, an international dialysis provider, a division of Gambro AB. From 1997 to 2000, he was Executive Vice President and Chief Operating Officer of Syncor International, an international provider of radiopharmaceuticals and medical imaging. Previously, Mr. Nutter held senior level positions at American Hospital Supply Corporation and Baxter International, Inc.

DR. MARK POPOVSKY joined our Company in 2000 as Senior Vice President and Corporate Medical Director. Prior to joining our Company, he served in the capacity of Chief Medical Officer & Chief Executive Officer at the American Red Cross – New England Region for 15 years. He is currently an Associate Professor of Pathology at Harvard Medical School and Beth Israel Deaconess Medical Center in Boston. Dr. Popovsky received his transfusion medicine training at the National Institutes of Health and Mayo Clinic. At Mayo Clinic he was the Director of Transfusion & Intravenous Services for 3 years. He serves on 7 editorial boards and is the author of more than three hundred peer-reviewed publications in transfusion medicine.

RONALD J. RYAN joined our Company in 1998 as Senior Vice President and Chief Financial Officer. In 2003, Mr. Ryan was named Vice President and Chief Financial Officer. Prior to joining our Company, he held the position of Chief Financial Officer and later Senior Vice President of Operations with Converse Inc. From 1984 to 1990, Mr. Ryan was Vice President of Finance and Business Planning for the Europe, Middle East and Africa Division of Bristol-Myers Squibb.

DR. YUTAKA SAKURADA joined our Company in 1991 as Board Member and President, Haemonetics Japan. In 2001, Dr. Sakurada was promoted to Chairman and CEO of Haemonetics Japan. In 2003, he was named President Japan/Asia in addition to his responsibilities as Chairman and CEO of Haemonetics Japan. Prior to joining our Company, Dr. Sakurada was Managing Director of Kuraray Plastic Company Ltd., a diversified synthetic fiber company, in Japan. From 1985 to 1989, Dr. Sakurada was a member of the Board of Kuraray.

WILLIAM STILL joined our Company in 2004 as Vice President of Strategic Marketing and Business Development. Prior to joining our Company, Mr. Still was Senior Director, Business Development for Advanced Respiratory Inc. From 1996 to 2001, he was with St. Jude Medical, most recently holding the position of Sr. Associate, Business Development. Mr. Still has also held the position of Finance Manager for St. Jude's Cardiac Surgery Group.

PART II

ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Our common stock is listed on the New York Stock Exchange under symbol HAE. The following table sets forth for the periods indicated the high and low sales prices of such common stock, which represent actual transactions as reported by the New York Stock Exchange.

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter
<i>Fiscal year ended April 2, 2005:</i>				
Market price of Common Stock				
High	\$31.70	\$33.25	\$37.25	\$45.23
Low	\$24.95	\$26.52	\$31.50	\$34.07
<i>Fiscal year ended April 3, 2004:</i>				
Market price of Common Stock				
High	\$23.75	\$24.30	\$24.00	\$32.50
Low	\$17.35	\$16.30	\$21.70	\$23.52

There were approximately 461 holders of record of the Company's common stock as of May 9, 2005. The Company has never paid cash dividends on shares of its common stock and does not expect to pay cash dividends in the foreseeable future.

ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA

Haemonetics Corporation and Subsidiaries Five-Year Review (in thousands, except share and employee data)

Summary of Operations	2005	2004	2003	2002	2001
Net revenues	\$383,598	\$364,229	\$336,956	\$319,969	\$293,860
Cost of goods sold	185,722	190,693	182,260	165,135	151,447
Gross profit	197,876	173,536	154,696	154,834	142,413
Operating expenses:					
Research and development	19,994	17,398	19,512	19,512	19,039
Selling, general and administrative	118,039	108,845	97,705	88,874	86,734
Acquired research and development	—	—	—	10,000	18,606
Other unusual charges	—	—	—	—	4,614
Total operating expenses	138,033	126,243	117,217	118,386	128,993
Operating income	59,843	47,293	37,479	36,448	13,420
Other income (expense), net	(2)	(1,481)	1,128	2,057	3,906
Income before provision for income taxes	59,841	45,812	38,607	38,505	17,326
Provision for income taxes	20,202	16,492	10,228	10,782	10,090
Income before cumulative effect of a change in accounting principle	39,639	29,320	28,379	27,723	7,236
Cumulative effect of a change in accounting principle	—	—	—	2,304 (a)	—
Net income	\$39,639	\$29,320	\$28,379	\$30,027	\$7,236
Income per share:					
Basic	\$ 1.55	\$ 1.20	\$ 1.15	\$ 1.15	\$ 0.29
Diluted	\$ 1.52	\$ 1.19	\$ 1.13	\$ 1.11	\$ 0.28
Weighted average number of shares	25,523	24,435	24,591	26,214	25,299
Common stock equivalents	622	260	457	941	706
Weighted average number of common and common equivalent shares	26,145	24,695	25,048	27,155	26,005
Financial and Statistical Data:	2005	2004	2003	2002	2001
Working capital	\$255,689	\$185,606	\$122,880	\$148,737	\$139,717
Current ratio	3.9	2.9	2.2	2.8	2.8
Property, plant and equipment, net	\$69,337	\$78,030	\$83,987	\$84,877	\$83,251
Capital expenditures	\$17,530	\$13,862	\$16,715	\$23,509	\$16,146
Depreciation and amortization	\$27,756	\$30,149	\$28,431	\$25,616	\$24,499
Total assets	\$467,757	\$407,394	\$359,485	\$364,921	\$345,314
Total debt	\$45,843	\$58,260	\$70,617	\$72,143	\$69,719
Stockholders' equity	\$355,135	\$279,749	\$223,237	\$236,824	\$215,516
Return on average equity	12.5%	11.7%	12.3%	13.3%	3.5%
Debt as a % of stockholders' equity	12.9%	20.8%	31.6%	30.5%	32.3%
Employees	1,546	1,438	1,497	1,498	1,357
Net revenues per employee	\$248	\$253	\$225	\$214	\$217

(a) Effective April 1, 2001, the Company adopted Statement of Financial Accounting Standards ("SFAS") No. 133, as amended, which resulted in the recognition of \$2.3 million as a cumulative effect of a change in accounting principle, net of tax. This amount is the change in the fair value of forward contracts related to forward points, which the Company excludes from its assessment of hedge effectiveness.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Our Business

We design, manufacture and market automated systems for the collection, processing and surgical salvage of donor and patient blood, including the single-use disposables used with our systems and related data management software. Our systems allow users to collect and process only the blood component(s) they target, plasma, platelets, or red blood cells, increasing donor and patient safety as well as collection efficiencies. Our systems consist of proprietary disposable sets that operate on our specialized equipment. Our data management systems are used by blood collectors to improve the safety and efficiency of blood collection logistics by eliminating previously manual functions at commercial plasma and not-for-profit blood banks.

We either sell our devices to customers (equipment revenue) or place our devices with customers subject to certain conditions. When the device remains our property, the customer has the right to use it for a period of time as long as they meet certain conditions we have established, which among other things, generally include one or more of the following:

- Purchase and consumption of a minimum level of disposable products
- Payment of monthly rental fees
- An asset utilization performance metric, such as performing a minimum level of procedures per month per device.

Our disposable revenue stream (including sales of disposables and fees for the use of our equipment) accounted for approximately 89% of our total revenues for fiscal years 2005, 2004 and 2003.

Product Families

Our donor products include systems to collect plasma, platelets and red cells from blood donors. We market our donor products primarily to blood collectors which include both for-profit plasma collectors and not-for-profit blood banks.

Our patient products include systems to collect (during and after surgery), wash and filter unwanted substances from the blood prior to reinfusion to the surgical patient. We market these patient products to hospitals and hospital service providers.

Miscellaneous and service revenue includes revenue generated from equipment repairs performed under preventive maintenance contracts or emergency service billings, as well as revenue from software sales.

Donor Products

Plasma

- ❖ Plasma collection systems – These systems are used by plasma collectors to collect the plasma component of a donor's whole blood. The plasma is sold to fractionators for processing into therapeutic pharmaceuticals and vaccines. Automated plasma collection is a safe and cost-effective improvement to manual (non-automated) plasma collection which is time-consuming, labor-intensive, produces relatively poor yields, and poses risk to donors. Currently the majority of plasma collections worldwide are automated collections.

Blood Bank

- ❖ Platelet collection systems – These systems are used by blood collectors to collect the platelet component of a donor's whole blood. Platelets are transfused to cancer patients whose platelets have been depleted as a result of chemotherapy. Before the advent of our platelet collection technology, the "pooling" or combination of platelets from six to eight different donors was the only alternative to

prepare a single therapeutic dose for transfusion to a patient. Our MCS® line of products allows the collection of a sufficient number of platelets from only one donor to produce one or two therapeutic doses.

- ❖ Cell Processing systems – These systems are used to freeze, thaw and wash red cells, which enables blood collectors to better manage their red cell inventories. In a liquid state, red cells must be transfused within 42 days whereas frozen red cells may be stored for up to ten years. Previous generation freezing technology required that red cells be transfused within 24 hours after thawing; our ACP® 215 systems allow red cells to be transfused for up to 14 days post thaw.
- ❖ Intravenous solutions – We contract manufacture sterile intravenous solutions for pharmaceutical customers. These solutions include generic drugs and other custom drug products.

Red Cell

- ❖ Red Cell collection systems-These systems are used to automate the collection of red cells from blood donors with protocols that allow for the collection of two units of red cells, a unit of red cells and a unit of plasma, or a unit of red cells and a unit of platelets. The systems improve the blood collector's operational efficiency by increasing the volume of blood components collected per donation event and eliminating manual processing. The most frequently used red cell collection protocol collects twice the number of red cells than the traditional (non-automated) collection method and helps blood systems address red cell shortages that commonly plague health care systems.

Patient Products

Surgical

- ❖ Surgical blood salvage systems – These systems are used by hospitals to collect a patient's own blood during or after surgery for reinfusion to the patient, mitigating or eliminating the need for transfusion of donated blood. We market Cell Saver® brand systems for higher blood loss procedures such as cardiovascular surgeries and the OrthoPAT® brand system for lower blood loss orthopedic surgeries. The cardioPAT brand system is our newest product, targeted at beating heart and other cardiovascular surgeries that result in bleeding during and after surgery.

Financial Summary

	For the years ended			%Increase/ (Decrease) 05 vs. 04	%Increase/ (Decrease) 04 vs. 03
	April 2, 2005	April 3, 2004	March 29, 2003		
<i>(in thousands, except per share data)</i>					
Net revenues	\$ 383,598	\$ 364,229	\$ 336,956	5.3%	8.1%
Gross profit	197,876	173,536	154,696	14.0%	12.2%
<i>% of net revenues</i>	<i>51.6%</i>	<i>47.6%</i>	<i>45.9%</i>		
Operating income	59,843	47,293	37,479	26.5%	26.2%
<i>% of net revenues</i>	<i>15.6%</i>	<i>13.0%</i>	<i>11.1%</i>		
Provision for income tax	20,202	16,492	10,228	22.5%	61.2%
<i>% of net revenues</i>	<i>5.3%</i>	<i>4.5%</i>	<i>3.0%</i>		
Net income	\$ 39,639	\$ 29,320	\$ 28,379	35.2%	3.3%
<i>% of net revenues</i>	<i>10.3%</i>	<i>8.0%</i>	<i>8.4%</i>		
Earnings per share-diluted	\$ 1.52	\$ 1.19	\$ 1.13	27.7%	5.3%

Net revenues for fiscal year 2005 increased 5.3% over fiscal year 2004. The favorable effects of foreign exchange contributed 5.0% of the increase with the remaining 0.3% resulting from increases in disposable revenues across our blood bank, red cell and surgical product lines due to unit increases and product mix shifts. These increases were

almost entirely offset by decreases in our plasma product line. Gross profit increased 14.0% over fiscal year 2004. The favorable effects of foreign exchange accounted for 9.8% of the increase in gross profit. The remaining 4.2% increase was due primarily to (i) a change in the mix of products being sold, ii) a decrease in depreciation on our equipment at customer sites and (iii) the excess and obsolete inventory provisions recorded in fiscal year 2004 related to the loss of our Alpha business and other matters. Operating income increased 26.5% over fiscal year 2004. The favorable effects of foreign exchange accounted for 27.8% of the increase. The remaining decrease of 1.3% resulted as gross profit improvements were more than offset by increases in operating expenses. Net income increased 35.2% over fiscal year 2004. The favorable effects of foreign exchange accounted for 28.9% of the increase. The remaining increase of 6.3% was due to a decrease in other expense, net, including interest expense and interest income, and lower tax expense.

Net revenues for fiscal year 2004 increased 8.1% over fiscal year 2003. The favorable effects of foreign exchange contributed 5.2% of the increase with the remaining 2.9% resulting from disposable increases in our blood bank, red cell, and surgical product lines and price increases, partly offset by decreases in our plasma product line. During fiscal year 2004, higher sales, the positive effects of foreign exchange, and cost reductions resulted in a gross profit increase of 12.2% and an operating income increase of 26.2% over fiscal year 2003. Net income increased 3.3% as compared to fiscal year 2003. This increase was a reflection of higher operating income partly offset by the increase in our income tax rate to 36% in fiscal year 2004 versus 26.5% in fiscal year 2003 due to a \$4.0 million tax refund recorded during fiscal year 2003.

The comparisons to fiscal year 2004 are impacted by the fact that fiscal year 2004 included 53 weeks, while fiscal years 2005 and 2003 each included 52 weeks, resulting from the policy that we use to determine our fiscal year end. The 53rd week in fiscal year 2004 gave rise to both additional revenues and operating expenses.

Market Trends

Plasma Market

Despite the continued increase in demand for plasma derived pharmaceuticals, particularly intravenous immunoglobulin (“IVIG”), three significant factors have influenced demand in the worldwide commercial plasma collection markets:

- The commercial plasma industry experienced significant consolidation among plasma collectors and fractionators. Industry consolidation impacts us when a collector changes the total number of its collection centers, the total number of collections performed per center or changes the plasma collection system (Haemonetics or competitive technology) used to perform some or all of those collections.
- In fiscal year 2005 fewer collection procedures were performed worldwide as a result of an oversupply of source plasma. In the U.S., our customers have recently observed an increase in the number of collection being performed by some customers. Accordingly, we believe that the inventory of source plasma has largely stabilized in the U.S. In Europe, we understand from customers that supply is beginning to come into alignment with demand and so we expect collections should level off in the near future. In Japan, there is a still an oversupply of plasma.
- Reimbursement guidelines affect the demand for end product pharmaceuticals.
- The newer plasma fractionation facilities make more efficient use of plasma in their production processes, utilizing less plasma to make similar quantities of pharmaceuticals and vaccines.

During the fourth quarter of fiscal year 2005, we entered into a long term supply agreement with ZLB Plasma Services (“ZLB”) to be its exclusive provider of plasma collection technology in the U.S.

Blood Bank Market

Despite modest to moderate increases in the demand for platelets in our major markets, improved collection efficiencies that increase the yield of platelets per collection have resulted in a flat market for disposables.

We expect our sales of intravenous solutions that we produce under contract for pharmaceutical companies to level off in the near term.

Red Cell Market

Blood demands, a need for greater operating efficiency, and a stringent regulatory environment continue to drive demand for our red cell products. Our business continues to grow as we gain new customers and expand our penetration at existing customer sites. Additionally, our sales continue to increase as more customers have migrated to our higher-priced filtered disposable sets which support our customers' good manufacturing processes by reducing manual processing.

Surgical Market

The part of the U.S. surgical blood salvage market that is aimed at higher blood loss cardiovascular procedures is declining and may continue to decline due to improved surgical techniques minimizing blood loss and a decrease in the number of open-heart (bypass) surgeries performed. As technology improves, as seen by the continuous improvements made to coronary stents and angioplasty, the preference of surgeons may shift to minimally invasive surgical procedures, further reducing the number of open-heart surgeries performed.

The main driver of growth is the lower blood loss orthopedic procedures served by our OrthoPAT system. We sell the OrthoPAT system through a distributor in the U.S. and direct in our other major markets.

RESULTS OF OPERATIONS

Net Revenues

By geography

<i>(in thousands)</i>	<u>April 2, 2005</u>	<u>April 3, 2004</u>	<u>March 29, 2003</u>	<u>% Increase / (Decrease) 05 vs. 04</u>	<u>% Increase / (Decrease) 04 vs. 03</u>
United States	\$ 131,632	\$ 126,872	\$ 127,241	3.8%	(0.3)%
International	<u>251,966</u>	<u>237,357</u>	<u>209,715</u>	<u>6.2</u>	<u>13.2</u>
Net revenues	<u>\$ 383,598</u>	<u>\$ 364,229</u>	<u>\$ 336,956</u>	<u>5.3%</u>	<u>8.1%</u>

International Operations and the Impact of Foreign Exchange

Our principal operations are in the U.S., Europe, Japan and other parts of Asia. Our products are marketed in more than 50 countries around the world via a direct sales force as well as independent distributors.

Approximately 66%, 65% and 62% of our revenues were generated outside the U.S. during fiscal year 2005, 2004 and 2003, respectively. During fiscal years 2005, 2004 and 2003, revenues from Japan accounted for approximately 27%, 27% and 28% of our total revenues, respectively and revenues from Europe comprised approximately 30%, 30% and 26% of our total revenues, respectively. These sales are primarily conducted in local currencies, specifically the Japanese Yen and the Euro. Accordingly, our results of operations are significantly affected by changes in the value of the Yen and the Euro relative to the U.S. dollar. The favorable effects of foreign exchange resulted in a 5.0 % increase in sales, which was the majority of the 5.3% increase in total sales from fiscal year 2004

to 2005. From fiscal year 2003 to fiscal year 2004, the favorable effects of foreign exchange accounted for 5.2% of the 8.1% increase in total sales.

Please see section entitled "Foreign Exchange" in management's discussion for a more complete discussion of how foreign currency affects our business and our strategy to manage this exposure.

By product type

<i>(in thousands)</i>	<u>April 2, 2005</u>	<u>April 3, 2004</u>	<u>March 29, 2003</u>	<u>% Increase/ (Decrease) 05 vs. 04</u>	<u>% Increase/ (Decrease) 04 vs. 03</u>
Disposables	\$ 342,730	\$ 325,540	\$ 298,220	5.3%	9.2%
Misc. & service Equipment	20,173 <u>20,695</u>	22,002 <u>16,687</u>	18,355 <u>20,381</u>	(8.3) <u>24.0</u>	19.9 <u>(18.1)</u>
Net revenues	<u>\$ 383,598</u>	<u>\$ 364,229</u>	<u>\$ 336,956</u>	<u>5.3%</u>	<u>8.1%</u>

Disposables revenue by product line

<i>(in thousands)</i>	<u>April 2, 2005</u>	<u>April 3, 2004</u>	<u>March 29, 2003</u>	<u>% Increase/ (Decrease) 05 vs. 04</u>	<u>% Increase/ (Decrease) 04 vs. 03</u>
<i>Donor:</i>					
Plasma	\$ 97,250	\$ 114,346	\$ 114,436	(15.0)%	(0.1)%
Blood Bank	130,427	112,209	99,921	16.2	12.3
Red Cells	<u>28,676</u>	<u>22,321</u>	<u>15,542</u>	<u>28.5</u>	<u>43.6</u>
Subtotal	<u>\$ 256,353</u>	<u>\$ 248,876</u>	<u>\$ 229,899</u>	<u>3.0%</u>	<u>8.3%</u>
<i>Patient:</i>					
Surgical	<u>86,377</u>	<u>76,664</u>	<u>68,321</u>	<u>12.7%</u>	<u>12.2%</u>
Total disposables revenue	<u>\$ 342,730</u>	<u>\$ 325,540</u>	<u>\$ 298,220</u>	<u>5.3%</u>	<u>9.2%</u>

Donor

Donor products include the plasma, blood bank and red cell product lines. Disposable revenue for donor products increased 3.0% during fiscal year 2005 compared to fiscal year 2004 and 8.3% during fiscal year 2004 compared to fiscal year 2003.

Plasma

During fiscal year 2005, plasma disposable revenue decreased 15.0%. The favorable effects of foreign exchange resulted in a 4.3% increase. Of the 19.3% remaining decrease, 58% is attributable to the U.S., 17% to Europe, 13% to Asia and 12% to Japan. Worldwide, fewer plasma collections were performed during the current fiscal year due to an over supply of source plasma. In the U.S. some customer specific factors also contributed to lower unit sales, including the loss of our largest U.S. customer, Alpha Therapeutic Corporation (“Alpha”), half way through fiscal year 2004 and the closings early in fiscal year 2005 of certain plasma collection facilities by another customer, ZLB.

During fiscal year 2004, plasma disposable revenues remained flat. The favorable effects of foreign exchange resulted in a 4.0% increase. An entirely offsetting decrease resulted in the latter half of the year with the loss of our largest U.S. customer, Alpha, partly offset by increases in Europe and Asia.

Blood Bank

During fiscal year 2005, blood bank disposable revenues increased 16.2%. The favorable effects of foreign exchange resulted in a 6.7% increase. Of the remaining 9.5% increase, 41% is attributable to the U.S., 28% to Asia and 27% to Japan. The increase in the U.S. was due to sales of intravenous solutions that we produce for pharmaceutical companies. The increase in Asia was due to lower than normal platelet collections during fiscal year 2004 due to the impact of the SARS virus. The increase in Japan was primarily due to a product mix shift from non-filtered platelet collection sets in fiscal year 2004 to higher-priced filtered sets in fiscal year 2005. Filtered sets include integrated blood filters to remove white cells from platelets.

During fiscal year 2004, blood bank disposable revenues increased 12.3%. The favorable effects of foreign exchange resulted in a 6.1% increase. The remaining 6.2% increase was a result of market share gains in Japan and Europe.

Red Cell

During fiscal year 2005, red cell disposable revenue increased 28.5%. The favorable effects of foreign exchange resulted in a 2.6% increase. Of the remaining 25.9% increase, 91% is attributable to the U.S. and 9% to Europe. The increases in both the U.S and Europe are primarily due to an increase in units sold and by a product shift to higher priced filtered sets, which include a filter to remove white blood cells from the collected blood.

During fiscal year 2004, red cell disposable revenue increased 43.6%. The favorable effects of foreign exchange resulted in a 4.3% increase. Of the remaining 39.3% increase, 97% is attributable to the U.S., primarily due to an increase in units sold and by a product shift to higher priced filtered sets, which include a filter to remove white blood cells from the collected blood.

Patient

Surgical

The surgical blood salvage product line has two major brand platforms: the Cell Saver[®] brand and the OrthoPAT[®] brand. During fiscal year 2005, disposable revenue for the surgical product line increased 12.7%. The favorable effects of foreign exchange accounted for a 5.1% increase with the remaining 7.6% increase attributable to increases in OrthoPAT disposable revenues.

Cell Saver disposables revenue increased 4.7% as compared to fiscal year 2004. The favorable effect of foreign exchange accounted for a 5.3% increase. The remaining 0.6% decrease was due to a reduction in U.S. unit sales partially offset by the favorable effect of price increases.

OrthoPAT disposable revenues increased 51.4%. The favorable effects of foreign exchange accounted for 4.1% of the increase. Of the remaining 47.3% increase, 61% is attributable to the U.S, 32% to Europe, and 5% to Japan. The increases are occurring as orthopedic surgeons continue to adopt surgical blood salvage as an effective alternative to patient pre-donation or donated blood during hip and knee replacements and other orthopedic surgeries and due to price improvements.

During fiscal year 2004, disposable revenue for the surgical product line, in total, increased 12.2%. The favorable effects of foreign exchange accounted for a 5.6% increase with the remaining 6.6% increase attributable to increases in OrthoPAT disposable revenues.

Other Revenues

<i>(in thousands)</i>	<u>April 2, 2005</u>	<u>April 3, 2004</u>	<u>March 29, 2003</u>	<u>% Increase/ (Decrease) 05 vs. 04</u>	<u>% Increase/ (Decrease) 04 vs. 03</u>
Miscellaneous & Service Equipment	\$ 20,173 <u>20,695</u>	\$ 22,002 <u>16,687</u>	\$ 18,355 <u>20,381</u>	(8.3)% <u>24.0</u>	19.9% <u>(18.1)</u>
Total other revenues	\$ 40,868	\$ 38,689	\$ 38,736	5.6%	(0.1)%

Our miscellaneous and service revenue includes revenue from repairs performed under preventive maintenance contracts or emergency service visits, spare part sales, various training programs and revenue from our software division, Fifth Dimension.

During fiscal year 2005, miscellaneous and service revenue decreased 8.3%. The favorable effects of foreign currency accounted for a 3.6% increase. Of the remaining 11.9% decrease, 74% was due to reduced software revenue from Fifth Dimension. Fifth Dimension currently sells its products primarily to plasma customers who have been negatively impacted by the recent volatility and consolidation in the worldwide commercial plasma collection market.

During fiscal year 2004, miscellaneous and service revenue increased 19.9%. The favorable effects of foreign currency accounted for a 4.3% increase. The remaining 15.6% increase resulted from several factors, most notably: (i) preventive maintenance contract increases in line with the increasing installed base of automated red cell collection devices, and (ii) increased software revenues from Fifth Dimension.

During fiscal year 2005, revenue from equipment sales increased 24.0%. The favorable effects of foreign exchange accounted for a 3.4% increase. The remaining increase of 20.6% was due to a large sale to a U.S. red cell customer during fiscal year 2005. Equipment sales fluctuate from period to period.

During fiscal year 2004, revenue from equipment sales decreased 18.1%. The favorable effects of foreign exchange accounted for a 6.8% increase. The remaining decrease of 24.9% was primarily attributable to fiscal year 2003 sales to a Japanese blood bank customer, to European plasma customers and to the U.S. military that were not duplicated in fiscal year 2004.

Gross profit

<i>(in thousands)</i>	April 2, 2005	April 3, 2004	March 29, 2003	% Increase/ (Decrease) 05 vs. 04	% Increase/ (Decrease) 04 vs. 03
Gross profit	\$197,876	\$173,536	\$154,696	14.0%	12.2%
<i>% of net sales</i>	51.6%	47.6%	45.9%		

During fiscal year 2005, gross profit increased 14.0%. The favorable effects of foreign exchange accounted for a 9.8% increase. The remaining 4.2% increase was due primarily to (i) a change in the mix of products being sold, ii) a decrease in depreciation on our equipment at customer sites and (iii) the excess and obsolete inventory provisions recorded in fiscal year 2004 related to the loss of our Alpha business and other matters.

During fiscal year 2004, gross profit increased 12.2%. The favorable effects of foreign exchange accounted for a 6.5% increase. The remaining 5.7% was due primarily to the impact of our higher sales including price increases.

Operating Expenses

<i>(in thousands)</i>	April 2, 2005	April 3, 2004	March 29, 2003	% Increase/ (Decrease) 05 vs. 04	% Increase/ (Decrease) 04 vs. 03
Research and development	\$ 19,994	\$ 17,398	\$ 19,512	14.9%	(10.8)%
Selling, general and administrative	118,039	108,845	97,705	8.4	11.4
Total operating expenses	\$ 138,033	\$ 126,243	\$ 117,217	9.30%	7.70%
<i>% of net sales</i>	36.0%	34.7%	34.8%		

Research and Development

During fiscal year 2005, research and development expenses increased 14.9%. The effect of foreign exchange accounted for 2.1% of the increase. Approximately 77% of the remaining 12.8% increase was due to the recognition of a \$1.7 million in impairment charge during the third quarter of fiscal year 2005 to write down the value of a previously acquired intangible asset. (See Note 6 for more discussion). The majority of the remaining increase was due to increased new product spending during the second half of fiscal year 2005. The most significant amount of the increased spending was directed to our new, multi component collection and Cell Saver platforms.

During fiscal year 2004, research and development expenses decreased 10.8%. The effect of foreign exchange accounted for a 0.5% increase. Approximately 80% of the remaining 11.3% decrease was related to lower costs as a result of personnel reductions.

Selling, General and Administrative

During fiscal year 2005, selling, general and administrative expenses increased 8.4%. The effect of foreign exchange accounted for 3.2% of the increase. The majority of the remaining 5.2% increase was due to (i) higher

personnel-related expenses in marketing and sales to support our new products and a higher level of sales, (ii) increased legal costs, (iii) increased costs due to compliance with Section 404 of the Sarbanes/Oxley Act of 2002 and (iv) increased costs associated with the conversion of the newly awarded ZLB business to our devices. The effect of these higher costs was partially offset by a year over year decrease in expense due to the \$2.7 million in severance costs during fiscal year 2004 as part of our reorganization.

During fiscal year 2004, selling, general and administrative expenses increased 11.4%. The effect of foreign exchange accounted for 6.8% of the increase. The remaining 4.6% increase was a result of the \$2.7 million of severance costs recognized in fiscal year 2004 related to our reorganization.

Operating income

<i>(in thousands)</i>	<u>April 2, 2005</u>	<u>April 3, 2004</u>	<u>March 29, 2003</u>	<u>% Increase/ (Decrease) 05 vs. 04</u>	<u>% Increase/ (Decrease) 04 vs. 03</u>
Operating Income	\$ 59,843	\$ 47,293	\$ 37,479	26.5%	26.2%
<i>% of net sales</i>	15.6%	13.0%	11.1%		

During fiscal year 2005, operating income increased 26.5%. The favorable effects of foreign exchange accounted for a 27.8% increase. The remaining 1.3% decrease is due to gross profit improvements that were offset by increases in operating expenses.

During fiscal year 2004, operating income increased 26.2%. The favorable effects of foreign exchange accounted for a 9.0% increase. The remaining 17.2% increase is a result of improving gross profit from sales increases and cost reductions and lower research and development spending partly offset by increased selling, general and administrative expenses due to our fiscal year 2004 reorganization.

Other income (expense), net

<i>(in thousands)</i>	<u>April 2, 2005</u>	<u>April 3, 2004</u>	<u>March 29, 2003</u>	<u>% Increase/ (Decrease) 05 vs. 04</u>	<u>% Increase/ (Decrease) 04 vs. 03</u>
Interest expense	\$ (2,361)	\$ (2,903)	\$ (3,495)	(18.7)%	(16.9)%
Interest income	2,233	1,848	2,214	20.8	(16.5)
Other income(expense), net	<u>126</u>	<u>(426)</u>	<u>2,409</u>	<u>(129.6)</u>	<u>(117.7)</u>
Total other (expense), income, net	<u>\$ (2)</u>	<u>\$ (1,481)</u>	<u>\$ 1,128</u>	<u>(99.9%)</u>	<u>(231.3%)</u>

During fiscal year 2005, several factors contributed to the decrease in total other expense, net: (i) a decrease in interest expense as we had lower average debt outstanding as compared to fiscal year 2004, (ii) an increase in interest income due to higher cash balances during the year, partially offset by \$0.6 million in interest income in fiscal year 2004 associated with an income tax refund and (iii) an increase in other income, net as a result of increases in points on forward contracts over fiscal year 2004. Points on forward contracts are amounts, either expensed or earned, based on the interest rate differential between two foreign currencies in a forward hedge contract.

During fiscal year 2004, interest expense decreased due to lower average debt balances as nearly all of our long-term debt is at fixed rates. Interest income decreased due primarily to lower investment yields on higher average cash investment balances. Other expense, net increased due primarily to a decrease in income earned from points on forward contracts in fiscal year 2004.

Taxes

	<u>April 2, 2005</u>	<u>April 3, 2004</u>	<u>March 29, 2003</u>	<u>% Increase/ (Decrease) 0 5vs. 04</u>	<u>% Increase/ (Decrease) 04 vs. 03</u>
Reported Tax Rate	33.8%	36.0%	26.5%	(2.2)%	9.5%

The reduction in the reported tax rate in fiscal year 2005 as compared to fiscal year 2004 resulted from several factors, including:

- An increase in tax exempt interest income
- Higher current year U.S. export tax benefits, as well as additional export tax benefits realized in connection with the filing of our fiscal year 2004 tax return.
- A reduction in foreign taxes, due to the reversal of previously established tax reserves related to a local Japanese tax matter.

The reduction in the reported tax rate in fiscal year 2004 as compared to fiscal year 2003 resulted from a \$4.0 million tax refund recorded in fiscal year 2003.

Critical Accounting Policies

Our significant accounting policies are summarized in Note 2 of our consolidated financial statements. While all of these significant accounting policies impact our financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements and require management to use a greater degree of judgment and/or estimates. Actual results may differ from those estimates.

The accounting policies identified as critical are as follows:

Revenue Recognition

We recognize revenues in accordance with generally accepted accounting principles (“GAAP”) as outlined in Staff Accounting Bulletin (“SAB”) No. 104 which requires that four basic criteria be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists, (2) product delivery, including customer acceptance, has occurred or services have been rendered, (3) the price is fixed or determinable and (4) collectibility is reasonably assured. We believe that our revenue recognition policy is critical because revenue is a very significant component of our results of operations.

We record software sales in accordance with Statement of Position (“SOP”) 97-2, “Software Revenue Recognition,” as amended, and in instances where services are essential to the functionality of the software, as is the case in the majority of Fifth Dimensions software sales, revenue is recognized in accordance with SOP 81-1, “Accounting for Performance of Construction-Type and Certain Production-Type Contracts.”

In accordance SOP 97-2, when the services are essential to the functionality of the software, or payment of the license fees are dependent upon the performance of the services, the software license, configuration, training and implementation fees are recognized under the contract method of accounting using labor hours to measure the completion percentage. In order to apply the contract method of accounting, management is required to estimate the number of hours needed to complete a particular project. As a result, recognized revenues and profits are subject to revisions as the contract progresses to completion.

Inventories

Inventories are stated at the lower of the actual cost to purchase and/or manufacture or the current estimated market value of the inventory. On a quarterly basis, inventory quantities on hand are reviewed and an analysis of the provision for excess and obsolete inventory is performed based primarily on our estimates of product demand and production requirements for the next twenty-four months. A change in the estimated timing or amount of demand for our products could result in additional provisions for excess inventory quantities on hand. Any significant unanticipated changes in demand could have a significant impact on the value of our inventory and reported operating results.

Goodwill and Other Intangible Assets

Purchase accounting requires extensive use of accounting estimates and judgments to allocate the purchase price to the fair market value of the assets and liabilities purchased, with the excess value, if any, being classified as goodwill. In addition, as described in Notes 3 and 6 of our consolidated financial statements, as a result of our acquisitions, values were assigned to intangible assets for patented and unpatented technologies and customer contracts and related relationships. For those assets with finite lives, useful lives were assigned to these intangibles and they will be amortized over their remaining life. We review our intangible assets and their related useful lives at least once a year to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. We conduct more frequent impairment assessments if certain conditions exist, including: a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the market place including changes in the prices paid for our products or changes in the size of the market for our products.

An impairment results if the carrying value of the asset exceeds the sum of the future undiscounted cash flows expected to result from the use and disposition of the asset. The amount of the impairment would be determined by comparing the carrying value to the fair value of the asset. Fair value is generally determined by calculating the present value of the estimated future cash flows using an appropriate discount rate. The projection of the future cash flows and the selection of a discount rate require significant management judgment. The key variables that management must estimate include sales volume, prices, inflation, product costs, capital expenditures and sales and marketing costs. For developed technology (patents and other technology) that have not been deployed we also must estimate the likelihood of both pursuing a particular strategy and the level of expected market adoption.

Significant judgment is involved in making these estimates. Future write-downs may be required if the value of the assets become impaired.

In fiscal year 2005, we recognized an impairment charge of \$1.7 million related to the excess of the carrying value over the fair market value of an intangible asset categorized as other technology. The impairment was triggered by our re-evaluation of our plans to deploy such technology.

Property, Plant and Equipment

Property, plant and equipment are depreciated over their useful lives. Useful lives are based on our estimate of the period that the assets will generate revenue. Any change in conditions that would cause us to change our estimate as to the useful lives of a group or class of assets may significantly impact our depreciation expense on a prospective basis. Haemonetics equipment includes devices that we have placed at our customers under contractual arrangements that allow them to use the device in exchange for rental payments or the purchase of disposables. In addition to periodically reviewing the useful lives of these devices, we also periodically perform reviews to determine if a group of these devices is impaired. To conduct these reviews we must estimate the future amount and timing of demand for these devices. Changes in expected demand can result in additional depreciation expense,

which is classified as cost of goods sold. Any significant unanticipated changes in demand could have a significant impact on the value of equipment and our reported operating results.

Income Taxes

In preparing our consolidated financial statements, income tax expense is calculated for all jurisdictions in which we operate. This process involves estimating actual current taxes due plus assessing temporary differences arising from differing treatment for tax and accounting purposes that are recorded as deferred tax assets and liabilities. Deferred tax assets are periodically evaluated to determine their recoverability. A valuation allowance is established and a corresponding additional income tax expense is recorded in our consolidated statement of income if their recovery is not likely. The provision for income taxes could also be materially impacted if actual taxes due differ from our earlier estimates. As of April 2, 2005, a valuation allowance of \$0.4 million existed on our balance sheet. The total net deferred tax asset as of April 2, 2005 was \$13.9 million.

We file income tax returns in all jurisdictions in which we operate. We established reserves to provide for additional income taxes that may be due in future years as these previously filed tax returns are audited. These reserves have been established based on management's assessment as to the potential exposure attributable to permanent differences and interest applicable to both permanent and temporary differences. All tax reserves are analyzed periodically and adjustments made as events occur that warrant modification.

Liquidity and Capital Resources

The following table contains certain key performance indicators that depict our liquidity and cash flow position:

	<u>April 2, 2005</u>	<u>April 3, 2004</u>	<u>March 29, 2003</u>
<i>(dollars in thousands)</i>			
Cash & cash equivalents	\$185,815	\$ 79,467	\$49,885
Working capital	\$255,689	\$185,606	\$122,880
Current ratio	3.9	2.9	2.2
Net cash (debt) position (1)	\$139,972	\$ 59,857	\$(20,773)
Days sales outstanding (DSO)	70	76	80
Disposables finished goods inventory turnover	4.9	5.7	4.6

(1) Net cash position is the sum of cash, cash equivalents and short-term investments less total debt.

Our primary sources of capital include cash and cash equivalents, internally generated cash flows and bank borrowings. We believe these sources to be sufficient to fund our requirements, which are primarily capital expenditures (including systems to improve our product life cycle management), acquisitions, new business and product development and working capital for at least the next twelve months.

	For the years ended			\$	\$
	<u>April 2, 2005</u>	<u>April 3, 2004</u>	<u>March 29, 2003</u>	<u>Increase/ (Decrease) 05vs 04</u>	<u>Increase/ (Decrease) 04 vs. 03</u>
		<i>(In thousands)</i>			
Net cash provided by (used in):					
Operating activities	\$ 71,207	\$ 76,771	\$ 46,978	\$ (5,564)	\$ 29,793
Investing activities	19,428	(48,682)	16,174	68,110	(64,856)
Financing activities	14,531	718	(49,001)	13,813	49,719
Effect of exchange rate changes on cash (1)	1,182	775	821	407	(46)
Net increase in cash and cash equivalents	<u>\$ 06,348</u>	<u>\$ 29,582</u>	<u>\$ 14,972</u>	<u>\$ 76,766</u>	<u>\$ 14,610</u>

Cash Flow Overview:

- (1) The balance sheet is affected by spot exchange rates used to translate local currency amounts into U.S. dollars. In comparing spot exchange rates at April 2, 2005 versus April 3, 2004 and at April 3, 2004 versus March 29, 2003, the European currencies, primarily the Euro, and the Yen have strengthened against the U.S. dollar. In accordance with GAAP, we have removed the effect of foreign currency throughout our cash flow statement, except for its effect on our cash and cash equivalents.

FISCAL 2005 AS COMPARED TO FISCAL 2004

Operating Activities:

Net cash provided by operating activities decreased \$5.6 million in 2005 due primarily to:

- \$14.0 million more cash used by inventory during fiscal year 2005 as inventory balances decreased during fiscal year 2004
- \$8.7 million more cash used due to increased income tax prepayments offset by;
- \$11.3 million more cash provided by net income adjusted for non-cash items
- \$7.5 million less cash used by accounts payable and accrued expenses due primarily to an increase in accrued income taxes in fiscal year 2005 versus fiscal year 2004

Investing Activities:

Net cash provided by investing activities increased \$68.1 million as a result of:

- \$77.3 million from the liquidation of our short-term investments in fiscal year 2005.
- \$4.1 million from an increase in proceeds from the sale of property, plant and equipment, due primarily to a significant sale of our equipment to a red cell customer during fiscal year 2005 offset by;
- \$9.6 million in increased investments. We invested \$5.0 million in the preferred stock of a private company, \$0.6 million to secure a related license agreement and \$4.0 million to acquire patents.
- \$3.7 million more capital expenditures during fiscal year 2005 as compared to fiscal year 2004.

During fiscal year 2005, we had capital expenditures of \$17.5 million.

Financing Activities:

Net cash provided by financing activities increased by \$13.8 million. The increase was due to:

- \$8.1 million in increased proceeds from stock option exercises during fiscal year 2005.

- \$5.7 million due to a fiscal year 2004 decrease in short-term debt in Japan for working capital purposes.

FISCAL 2004 AS COMPARED TO FISCAL 2003

Operating Activities:

Net cash provided by operating activities increased \$29.8 million in 2004 due primarily to:

- a \$2.7 million increase in net income adjusted for non-cash items,
- a \$12.1 million increase in cash provided from accounts receivable due to the timing of customer payments, particularly in Japan, with the 53rd week in fiscal year 2004, and
- \$14.8 million increase in cash provided by reduced investments in inventory.

Investing Activities:

Net cash used in investing activities increased \$64.9 million as a result of:

- \$71.3 million in increased cash spent on short-term investments in fiscal year 2004 due to the reinvestment in fiscal year 2004 of investments liquidated in fiscal year 2003 offset by;
- \$0.8 million from an increase in proceeds in fiscal year 2004 as compared to fiscal year 2003 from the sale of property, plant and equipment,
- \$2.8 million less cash spent on capital expenditures during fiscal year 2004, and
- \$2.8 million more spent in fiscal year 2003 for pathogen reduction technology.

During fiscal year 2004, we had capital expenditures of \$13.9 million.

Financing Activities:

Net cash provided by financing activities increased by \$49.7 million. The change was driven by the following factors:

- \$50.2 million repurchases of our stock in fiscal year 2003 and no repurchases in fiscal year 2004,
- \$13.2 million from increased stock option exercises in fiscal year 2004, and
- a \$13.7 million decrease in the short-term debt primarily in Japan for working capital purposes.

Contractual Obligations and Contingencies

A summary of our contractual and commercial commitments as of April 2, 2005, is as follows (for more information concerning our debt see Note 7 to the consolidated financial statements and for our operating lease obligations see Note 9):

Contractual Obligations <i>(in thousands)</i>	Payments Due by Period				
	Total	Less than 1 year	1-3 years	3-5 years	After 5 years
Debt	\$45,843	\$26,612	\$12,555	\$1,332	\$5,344
Operating Leases	15,435	6,152	5,911	2,337	1,035
Purchase commitments*	47,766	47,068	698	—	—
Total	\$109,044	\$79,832	\$19,164	\$3,669	\$6,379

- * Includes amounts we are committed to spend on purchase orders entered in the normal course of business for capital equipment and for the purpose of manufacturing our products including contract manufacturers, specifically Nova Biomedical, for the purchase of devices and JMS Co. LTD, and Kawasumi Laboratories for the manufacture of certain disposable products. The majority of our operating expense spending does not require any advance commitment.

Contingent Commitments

As a result of our fiscal year 2005 license arrangement for blood processing technology, our fiscal year 2002 acquisition of Fifth Dimension, and our fiscal year 2002 agreement with Baxter related to pathogen reduction technology, we are contingently obligated to make certain payments. The fiscal year 2005 license arrangement involves certain potential payments of up to \$12.4 million if the technology reaches certain performance milestones. In addition, if the specified deliverables are completed, the agreement calls for minimum royalty payments for future commercial sales of products that incorporate this technology. The Fifth Dimension acquisition involves certain potential payments of up to \$4.1 million (of which \$2.0 million has already been paid). Therefore our current potential obligation is \$2.1 million should sales of the Fifth Dimension software products exceed certain cumulative levels prior to the end of fiscal year 2008. The pathogen reduction agreement calls for us to make total potential payments of up to \$14.5 million as regulatory approvals are received in various markets. Out of the \$14.5 million of potential payments, we paid \$3.8 million in the fourth quarter of fiscal year 2003 as initial regulatory approvals were obtained in the European market. No payments were made in fiscal year 2005 or fiscal year 2004. If and when additional approvals are obtained, we will capitalize these payments as other technology, an intangible asset and amortize over their useful life.

Inflation

We do not believe that inflation has had a significant impact on our results of operations for the periods presented. Historically, we believe we have been able to minimize the effects of inflation by improving our manufacturing and purchasing efficiency, by increasing employee productivity and by adjusting the selling prices of new products we introduce.

Foreign Exchange

Approximately 66% of our sales are generated outside the U.S. in local currencies, yet our reporting currency is the U.S. dollar. Our primary foreign currency exposures in relation to the U.S. dollar are the Japanese Yen and the Euro. Foreign exchange risk arises because we engage in business in foreign countries in local currency. Exposure is partially mitigated by producing and sourcing product in local currency and expenses incurred by local sales offices. However, whenever the U.S. dollar strengthens relative to the other major currencies, there is an adverse affect on our results of operations and alternatively, whenever the U.S. dollar weakens relative to the other major currencies there is a positive effect on our results of operations.

It is our policy to minimize for a period of time, the unforeseen impact on our financial results of fluctuations in foreign exchange rates by using derivative financial instruments known as forward contracts to hedge the anticipated cash flows from forecasted foreign currency denominated sales. Hedging through the use of forward contracts does not eliminate the volatility of foreign exchange rates, but because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation. We enter into forward contracts that mature one month prior to the anticipated timing of the forecasted foreign currency denominated sales. These contracts are designated as cash flow hedges intended to lock in the expected cash flows of forecasted foreign currency denominated sales at the available spot rate. Actual spot rate gains and losses on these contracts are recorded in sales, at the same time the underlying transactions being hedged are recorded.

We compute a composite rate index for purposes of measuring, comparatively, the change in foreign currency hedge spot rates from the hedge spot rates of the corresponding period in the prior year. The relative value of currencies in the index is weighted by sales in those currencies. The composite was set at 1.00 based upon the weighted rates at March 31, 1997. The composite rate is presented in the period corresponding to the maturity of the underlying forward contracts.

The favorable or (unfavorable) changes are in comparison to the same period of the prior year. A favorable change is presented when we will obtain relatively more U.S. dollars for each of the underlying foreign currencies than we did in the prior period. An unfavorable change is presented when we obtain relatively fewer U.S. dollars for each of the underlying foreign currencies than we did in the prior period. These indexed hedge rates impact sales, and as a result also gross profit, operating income and net income, in our consolidated financial statements. The final impact of currency fluctuations on the results of operations is dependent on the local currency amounts hedged and the actual local currency results

		Composite Index Hedge Spot Rates	Favorable / (Unfavorable) Change versus Prior Year
FY2002	Q1	0.99	5.2%
	Q2	0.97	3.3%
	Q3	1.01	(8.6%)
	Q4	1.05	(7.5%)
2002	Total	1.00	(2.0%)
FY2003	Q1	1.09	(8.9%)
	Q2	1.08	(10.3%)
	Q3	1.10	(8.1%)
	Q4	1.17	(11.0%)
2003	Total	1.11	(9.5%)
FY2004	Q1	1.13	(3.6%)
	Q2	1.05	3.6%
	Q3	1.06	3.2%
	Q4	1.01	15.9%
2004	Total	1.06	4.9%
FY2005	Q1	0.97	15.7%
	Q2	0.99	5.1%
	Q3	0.92	15.5%
	Q4	0.89	14.1%
2005	Total	0.94	12.7%
FY2006	Q1	0.92	5.2%
	Q2	0.91	9.1%
	Q3	0.87	5.7%
	Q4	0.86	2.8%
2006	Total	0.89	5.1%
FY2007	Q1	0.89*	4.5%

NOTE: Represents hedges for April and May FY07.

New Accounting Pronouncements

On December 16, 2004, the Financial Accounting Standards Board ("FASB") issued FASB Statement No. 123 (revised 2004), "Shared-Based payments", ("SFAS No. 123R") which is a revision of FASB Statement No. 123, ("SFAS No. 123") Accounting for Stock Based Compensation. SFAS No. 123R supersedes Accounting Principles Board ("APB") Opinion No. 25, Accounting for Stock Issued to Employees. SFAS No.123R requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statements based on their fair values. The disclosure only approach permitted by SFAS No. 123 and elected by us, is no longer an alternative effective with our fiscal year 2007. Accordingly, the adoption of SFAS No. 123R's fair value method will have a significant impact on the results of operations, although it will have no impact on our overall financial position. The impact of adoption of SFAS No. 123R cannot be predicted at this time because it will depend on levels of share-based payments granted in the future. We are currently evaluating which fair value method we will use to adopt the requirements of SFAS No. 123R. However, had we adopted SFAS No.

123R in prior periods, the impact of that standard would have approximated the impact of SFAS No. 123 as described in the disclosure of pro forma net income and earnings per share in Note 2 to our consolidated financial statements.

The FASB recently issued, FASB Statement SFAS No. 151, "Inventory Costs," ("SFAS No. 151") an amendment of Accounting Research Bulletin ("ARB") No. 43, Chapter 4. The amendment clarifies that abnormal amounts of idle facility expense, freight, handling costs, and wasted materials should be recognized as current-period charges. It also clarifies that the required allocation of fixed production overheads to inventory based on the normal capacity of the production facilities. We will adopt SFAS No. 151 on April 3, 2005 at the beginning of our fiscal year 2006. The clarification provided by SFAS No. 151 is consistent with our current accounting policy, and accordingly we expect no impact from the adoption of this statement.

In October 2004, the American Jobs Creation Act of 2004 ("AJCA") was enacted. The AJCA provides a deduction from income for qualified domestic production activities that will be phased in beginning in 2006 and fully implemented in 2010. The AJCA also provides a two-year phase-out for the existing extra-territorial income exclusion on foreign sales. In December 2004, the FASB issued FASB Staff Position ("FSP") No. 109-1, "Application of FASB Statement No. 109, Accounting for Income Taxes, to the Tax Deduction on Qualified Production Activities by the American Jobs Creation Act of 2004. It is our intent to maximize this deduction and we are currently evaluating the impact this will have on our future consolidated statements of income and financial position.

The AJCA also provides a temporary incentive for U.S. corporations to repatriate accumulated income earned abroad by providing an 85% dividends received deduction, provided certain criteria are met. At this time it is not practical to determine if this temporary incentive is appropriate for us or to estimate the amount of tax that would be required to be provided upon repatriation. Accordingly, until our evaluation is complete, we will not change our current intention to permanently reinvest accumulated earnings of our foreign subsidiaries.

Cautionary Statement Regarding Forward-Looking Information

Statements contained in this report, as well as oral statements we make which are prefaced with the words "may," "will," "expect," "anticipate," "continue," "estimate," "project," "intend," "designed," and similar expressions, are intended to identify forward looking statements regarding events, conditions, and financial trends that may affect our future plans of operations, business strategy, results of operations, and financial position. These statements are based on our current expectations and estimates as to prospective events and circumstances about which we can give no firm assurance. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made. As it is not possible to predict every new factor that may emerge, forward-looking statements should not be relied upon as a prediction of our actual future financial condition or results. These forward-looking statements, like any forward-looking statements, involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. Such risks and uncertainties include technological advances in the medical field and our standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand and market acceptance of our products, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, the impact of industry consolidation, foreign currency exchange rates, changes in customers' ordering patterns, the effect of industry consolidation as seen in the Plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate. The foregoing list should not be construed as exhaustive.

ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company's exposures relative to market risk are due to foreign exchange risk and interest rate risk.

FOREIGN EXCHANGE RISK

See the section entitled Foreign Exchange for a discussion of how foreign currency affects our business. It is our policy to minimize for a period of time, the unforeseen impact on our financial results of fluctuations in foreign exchange rates by using derivative financial instruments known as forward contracts to hedge anticipated cash flows from forecasted foreign currency denominated sales. We do not use the financial instruments for speculative or trading activities. At April 2, 2005, we held the following significant foreign exchange contracts to hedge the anticipated cash flows from forecasted foreign currency denominated sales outstanding:

<u>Hedged Currency</u>	<u>(BUY) / SELL Local Currency</u>	<u>Weighted Spot Contract Rate</u>	<u>Weighted Forward Contract Rate</u>	<u>Fair Value</u>	<u>Maturity</u>
Euro	5,300,000	\$1.200	\$1.198	\$(501,792)	Apr-May 2005
Euro	7,400,000	\$1.227	\$1.226	\$(514,750)	June-Aug 2005
Euro	8,300,000	\$1.302	\$1.308	\$50,191	Sep-Nov 2005
Euro	8,850,000	\$1.306	\$1.320	\$105,808	Dec 2005-Feb 2006
Japanese Yen	1,050,000,000	110.9 per US\$	108.6 per US\$	\$(133,072)	Apr-May 2005
Japanese Yen	1,720,000,000	110.0 per US\$	107.7 per US\$	\$(187,848)	June-Aug 2005
Japanese Yen	1,835,000,000	105.5 per US\$	102.9 per US\$	\$416,930	Sep-Nov 2005
Japanese Yen	1,625,000,000	104.5 per US\$	101.3 per US\$	\$453,353	Dec 2005-Feb 2006
				<u>\$(311,180)</u>	

We estimate the change in the fair value of all forward contracts assuming both a 10% strengthening and weakening of the U.S. dollar relative to all other major currencies. In the event of a 10% strengthening of the U.S. dollar, the change in fair value of all forward contracts would result in a \$11.5million increase in the fair value of the forward contracts; whereas a 10% weakening of the U.S. dollar would result in a \$12.9 million decrease in the fair value of the forward contracts.

INTEREST RATE RISK

All of our long-term debt is at fixed rates. Accordingly, a change in interest rates has an insignificant effect on our interest expense amounts. The fair value of our long-term debt, however, does change in response to interest rates movements due to its fixed rate nature. At April 2, 2005, the fair value of our long-term debt was approximately \$1.6 million higher than the value of the debt reflected on our financial statements. This higher fair market is entirely related to our \$11.4 million, 7.05% fixed rate senior notes and our \$7.8 million, 8.41% real estate mortgage.

At April 3, 2004, the fair value of our long-term debt was approximately \$2.6 million higher than the value of the debt reflected on our financial statements. This higher fair market is entirely related to our \$17.1 million, 7.05% fixed rate senior notes and our \$8.3 million, 8.41% real estate mortgage.

Using scenario analysis, if we changed the interest rate on all long-term maturities by 10% from the rate levels that existed at April 2, 2005 the fair value of our long-term debt would change by approximately \$0.3 million.

Concentration of Credit Risk and Significant Customers

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, accounts receivable and investment in sales type lease receivables. Sales to one unaffiliated Japanese customer, the Japanese Red Cross Society, amounted to \$91.0 million, \$87.6 million and \$79.0 million in 2005, 2004 and 2003, respectively. Accounts receivable balances attributable to this customer accounted for 18.7%, 22.0% and 23.6% of our consolidated accounts receivable at fiscal year 2005, 2004 and 2003, respectively. While the accounts receivable related to the Japanese Red Cross Society may be significant, we do not believe the credit loss risk to be significant given the consistent payment history by this customer.

Certain other markets and industries can expose us to concentrations of credit risk. For example, in our commercial plasma business, we tend to have only a few customers in total but they are large in size. As a result our accounts receivable extended to any one of these commercial plasma customers can be somewhat significant at any point in time.

ITEM 8 FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

HAEMONETICS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share data)

	Years Ended		
	April 2, 2005	April 3, 2004	March 29, 2003
Net revenues	\$ 383,598	\$ 364,229	\$ 336,956
Cost of goods sold	185,722	190,693	182,260
Gross profit	197,876	173,536	154,696
Operating expenses:			
Research and development	19,994	17,398	19,512
Selling, general and administrative	118,039	108,845	97,705
Total operating expenses	138,033	126,243	117,217
Operating income	59,843	47,293	37,479
Interest expense	(2,361)	(2,903)	(3,495)
Interest income	2,233	1,848	2,214
Other income (expense), net	126	(426)	2,409
Income before provision for income taxes	59,841	45,812	38,607
Provision for income taxes	20,202	16,492	10,228
Net income	\$ 39,639	\$ 29,320	\$ 28,379
Basic income per common share			
Net income	\$ 1.55	\$ 1.20	\$ 1.15
Income per common share assuming dilution			
Net income	\$ 1.52	\$ 1.19	\$ 1.13
Weighted average shares outstanding			
Basic	25,523	24,435	24,591
Diluted	26,145	24,695	25,048

HAEMONETICS CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)

	April 2, 2005	April 3, 2004
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 185,815	\$ 79,467
Short term investments	—	38,650
Accounts receivable, less allowance of \$2,074 in 2005 and \$2,261 in 2004	80,719	82,640
Inventories, net	53,088	52,235
Deferred tax asset, net	13,785	21,856
Prepaid expenses and other current assets	10,204	6,601
Total current assets	343,611	281,449
Property, plant and equipment:		
Land, building and building improvements	36,579	33,966
Plant equipment and machinery	66,578	63,866
Office equipment and information technology	39,333	39,600
Haemonetics equipment	130,128	131,689
Total property, plant and equipment	272,618	269,121
Less: accumulated depreciation	203,281	191,091
Net property, plant and equipment	69,337	78,030
Other assets:		
Other intangibles, less amortization of \$9,327 in 2005 and \$5,569 in 2004	25,827	24,784
Goodwill	18,193	17,242
Deferred tax asset, long term	102	—
Other long-term assets	10,687	5,889
Total other assets	54,809	47,915
Total assets	\$ 467,757	\$ 407,394
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Notes payable and current maturities of long-term debt	\$ 26,612	\$ 32,818
Accounts payable	11,111	14,249
Accrued payroll and related costs	15,998	14,547
Accrued income taxes	12,417	7,967
Other liabilities	21,784	26,262
Total current liabilities	87,922	95,843
Deferred tax liability, net	—	1,682
Long-term debt, net of current maturities	19,231	25,442
Other long-term liabilities	5,469	4,678
Commitments and contingencies (Note 9)		
Stockholders' equity:		
Common stock, \$0.01 par value; Authorized - 80,000,000 shares;		
Issued – 26,177,468 shares in 2005 and 32,647,910 shares in 2004	262	326
Additional paid-in capital	121,803	127,744
Retained earnings	233,769	322,291
Accumulated other comprehensive loss	(699)	(6,535)
Stockholders' equity before treasury stock	355,135	443,826
Less: Treasury stock at cost - 7,568,289 shares in 2004	—	164,077
Total stockholders' equity	355,135	279,749
Total liabilities and stockholders' equity	\$ 467,757	\$ 407,394

The accompanying notes are an integral part of these consolidated financial statements.

HAEMONETICS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(in thousands)

	Common Stock		Additional Paid-in Capital	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Loss	Total Stockholders' Equity	Comprehensive Income
	Shares	\$'s						
Balance, March 30, 2002	31,454	\$315	\$104,261	(\$115,949)	\$264,592	(\$16,395)	\$236,824	
Employee stock purchase plan	—	—	16	780	—	—	796	
Exercise of stock options and related tax benefit	211	2	4,493	—	—	—	4,495	
Purchase of treasury stock	—	—	—	(50,166)	—	—	(50,166)	
Net income	—	—	—	—	28,379	—	28,379	\$28,379
Net change in minimum pension liability	—	—	—	—	—	(424)	(424)	(424)
Foreign currency translation adjustment	—	—	—	—	—	8,028	8,028	8,028
Unrealized loss on derivatives	—	—	—	—	—	(4,695)	(4,695)	(4,695)
Comprehensive income	—	—	—	—	—	—	—	\$31,288
Balance, March 29, 2003	31,665	\$317	\$108,770	(\$165,335)	\$292,971	(\$13,486)	\$223,237	
Employee stock purchase plan	—	—	(393)	1,258	—	—	865	
Exercise of stock options and related tax benefit	983	9	19,367	—	—	—	19,376	
Net income	—	—	—	—	29,320	—	29,320	\$29,320
Net change in minimum pension liability	—	—	—	—	—	35	35	35
Foreign currency translation adjustment	—	—	—	—	—	8,934	8,934	8,934
Unrealized loss on derivatives	—	—	—	—	—	(2,018)	(2,018)	(2,018)
Comprehensive income	—	—	—	—	—	—	—	\$36,271
Balance, April 3, 2004	32,648	\$326	\$127,744	(\$164,077)	\$322,291	(\$6,535)	\$279,749	
Employee stock purchase plan	—	—	10	919	—	—	929	
Exercise of stock options and related tax benefit	1,055	11	28,971	—	—	—	28,982	
Net income	—	—	—	—	39,639	—	39,639	\$39,639
Net change in minimum pension liability	—	—	—	—	—	129	129	129
Foreign currency translation adjustment	—	—	—	—	—	1,939	1,939	1,939
Unrealized loss on derivatives	—	—	—	—	—	3,768	3,768	3,768
Comprehensive income	—	—	—	—	—	—	—	\$45,475
Reclassification of treasury stock to common stock	(7,526)	(75)	(34,922)	163,158	(128,161)	—	—	—
Balance, April 2, 2005	26,177	\$262	\$121,803	—	\$233,769	(\$699)	\$355,135	

The accompanying notes are an integral part of these consolidated financial statements.

HAEMONETICS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

	April 2, 2005	Years Ended April 3, 2004	March 29, 2003
Cash Flows from Operating Activities:			
Net income	\$39,639	\$29,320	\$28,379
Adjustments to reconcile net income to net cash provided by operating activities:			
Non cash items:			
Depreciation and amortization	27,576	30,149	28,431
Impairment of intangible assets	1,700	—	—
Deferred tax expense	3,965	1,338	4,030
Gain on sales of plant, property and equipment	(3,594)	(1,547)	(873)
Tax benefit related to exercise of stock options	3,729	2,191	538
Unrealized gain from hedging activities	(1,296)	(984)	(2,762)
Change in operating assets and liabilities:			
Decrease (increase) in accounts receivable, net	3,025	3,697	(8,365)
(Increase) decrease in inventories	(4,730)	9,267	(5,486)
(Increase) decrease in prepaid income taxes	(4,274)	4,408	(1,315)
Decrease in other assets and other long-term liabilities	2,121	3,123	2,340
Increase (decrease) in accounts payable and accrued expenses	3,346	(4,191)	2,061
Net cash provided by operating activities	<u>71,207</u>	<u>76,771</u>	<u>46,978</u>
Cash Flows from Investing Activities:			
Purchases of short-term investments	(49,800)	(44,150)	(11,670)
Gross proceeds from sale of short-term investments	88,450	5,500	44,306
Capital expenditures on property, plant and equipment	(17,530)	(13,862)	(16,715)
Proceeds from sale of property, plant and equipment	8,917	4,850	4,053
Acquisition of patents	(4,019)	—	—
Acquisition of software development company and milestone payments	(1,020)	(1,020)	(3,800)
Investment in preferred stock	(5,570)	—	—
Net cash provided by (used in) investing activities	<u>19,428</u>	<u>(48,682)</u>	<u>16,174</u>
Cash Flows from Financing Activities:			
Payments on long-term real estate mortgage	(457)	(420)	(386)
Net (decrease) increase in short-term revolving credit agreements	(5,480)	(11,198)	2,513
Payments on long-term credit agreements	(5,714)	(5,714)	(5,714)
Employee stock purchase plan	929	865	796
Exercise of stock options	25,253	17,185	3,956
Purchase of treasury stock	—	—	(50,166)
Net cash provided by (used in) financing activities	<u>14,531</u>	<u>718</u>	<u>(49,001)</u>
Effect of Exchange Rates on Cash and Cash Equivalents	1,182	775	821
Net Increase in Cash and Cash Equivalents	<u>106,348</u>	<u>29,582</u>	<u>14,972</u>
Cash and Cash Equivalents at Beginning of Year	<u>79,467</u>	<u>49,885</u>	<u>34,913</u>
Cash and Cash Equivalents at End of Period	<u><u>\$185,815</u></u>	<u><u>\$79,467</u></u>	<u><u>\$49,885</u></u>
Non-cash Investing and Financing Activities:			
Transfers from inventory to fixed assets for placements of Haemonetics equipment	<u>\$ 4,180</u>	<u>\$ 7,478</u>	<u>\$ 10,699</u>
Reclassification from long-term credit agreements to short-term credit agreements	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 2,489</u>
Supplemental Disclosures of Cash Flow Information:			
Interest paid	<u>\$ 2,357</u>	<u>\$ 2,806</u>	<u>\$ 3,227</u>
Income taxes paid	<u>\$ 12,764</u>	<u>\$ 14,014</u>	<u>\$ 6,625</u>

The accompanying notes are an integral part of these consolidated financial statements.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

1. DESCRIPTION OF THE BUSINESS

We design, manufacture and market automated systems and single-use disposables for the collection, processing and surgical salvage of blood as well as associated data management technology. In addition, we are engaged in marketing partnerships under which we sell other products supporting the blood collection and surgical industries.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Fiscal Year

Our fiscal year ends on the Saturday closest to the last day in March. Fiscal year 2005 includes 52 weeks, fiscal year 2004 included 53 weeks and fiscal year 2003 included 52 weeks.

Principles of Consolidation

The accompanying consolidated financial statements include all accounts including those of our subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Revenue Recognition

Our revenue recognition policy is to recognize revenues from product sales, software and services in accordance with SAB No. 104, "Revenue Recognition in Financial Statements" which requires that revenues are recognized when persuasive evidence of an arrangement exists, product delivery, including customer acceptance, has occurred or services have been rendered, the price is fixed or determinable and collectibility is reasonably assured.

Product Revenues

Product sales consist of the sale of our equipment devices, the related disposables used in these devices and intravenous solutions manufactured for pharmaceutical companies. On product sales, revenue is recognized when both the title and risk of loss have transferred to the customer as determined by the shipping terms and all post delivery obligations have been achieved to the full satisfaction of the customer. Examples of common post delivery obligations are installation and training. For product sales to our distributors, we recognize revenue for both equipment and disposables revenue upon shipment of these products to our distributors. Our standard contracts with our distributors state that title to the equipment passes to the distributors at point of shipment to a distributor's location. The distributors are responsible for shipment to the end customer along with installation, training and acceptance of the equipment by the end customer. All shipments to distributors are at contract prices and payment is not contingent upon resale of the product.

Software Revenues

Software sales consist of the sale of our donor management information technology developed by our subsidiary, Fifth Dimension. In most cases, as services are essential to the functionality of our software revenue is recognized in accordance with SOP 81-1, "Accounting for Performance of Construction-Type and Certain Production-Type Contracts" which requires that the software license, configuration, training and implementation fees are recognized under the contract method of accounting using labor hours to measure the completion percentage. As the number of hours through completion may change, our revenues and profits are subject to revisions as the contract progresses. We recorded \$4.7 million, \$6.6 million and \$5.0 million of software revenue in fiscal year 2005, 2004 and 2003, respectively.

Service Revenues

Service revenues are recognized ratably over the contractual periods or as the services are provided.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

Multiple element arrangements

When more than one element such as equipment, disposables and services are contained in a single arrangement, we allocate revenue between the elements based on each element's relative fair value, provided that each element meets the criteria for treatment as a separate unit of accounting. An item is considered a separate unit of accounting if it has value to the customer on a stand alone basis and there is objective and reliable evidence of the fair value of the undelivered items. Fair value is generally determined based upon the price charged when the element is sold separately.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could vary from the amounts derived from our estimates and assumptions.

Translation of Foreign Currencies

All assets and liabilities of foreign subsidiaries are translated at the rate of exchange at year-end while sales and expenses are translated at an average rate in effect during the year. The net effect of these translation adjustments is shown in the accompanying financial statements as a component of stockholders' equity. Foreign currency transaction gains and losses are included in other income, net on the consolidated statements of income.

Cash and Cash Equivalents

Cash equivalents include various instruments such as money market funds, U.S. government obligations and commercial paper with maturities of three months or less at date of acquisition. Cash and cash equivalents are recorded at cost, which approximates fair market value.

Short Term Investments

As of April 3, 2004, all our short term investments, consisted of auction rate debt securities and were categorized as available for sale under the provisions of SFAS Statement No. 115, "Accounting for Certain Investments in Debt and Equity Securities." Accordingly, our investments in these securities are recorded at cost, which approximates fair value due to their variable interest rates, which typically reset every 28 to 35 days. Despite the long-term nature of the stated contractual maturities of these investments, we have the ability to liquidate these securities prior to their stated maturity date. As a result of the resetting variable rates, we had no cumulative gross unrealized or realized holding gains or losses from these investments during fiscal year 2005 or 2004. All income generated from these investments was recorded as interest income. As of April 2, 2005, we held no short term investments. Proceeds from these short term investments totaled approximately \$88.5 million and \$5.5 million during fiscal year 2005 and fiscal year 2004, respectively. During fiscal year 2003, we held short-term investments, other than auction rate securities, with maturities greater than three months but equal to or less than 12 months. All of these investments were classified as available-for-sale and were carried at fair value with realized gains and losses calculated based on the specific identification method and included in other income, net on our consolidated statements of income. During 2003, proceeds from these investment securities sales totaled approximately \$44.3 million with realized gains of approximately \$30,300.

Allowance for Doubtful Accounts

We establish a specific allowance for customers when we become aware they will not be able to meet their financial obligation. Customer accounts are reviewed individually on a regular basis and appropriate reserves are established as deemed appropriate. We also maintain a general reserve using a percentage based upon an aging method. We establish percentages for balances not yet due and past due accounts based on past experience.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

Concentration of Credit Risk and Significant Customers

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, accounts receivable and investment in sales type lease receivables. Sales to one unaffiliated Japanese customer, the Japanese Red Cross Society, amounted to \$91.0 million, \$87.6 million and \$79.0 million for 2005, 2004 and 2003, respectively. Accounts receivable balances attributable to this customer accounted for 18.7%, 22.0% and 23.6% of our consolidated accounts receivable at fiscal year end 2005, 2004 and 2003, respectively. While the accounts receivable related to the Japanese Red Cross Society may be significant, we do not believe the credit loss risk to be significant given the consistent payment history by this customer.

Cost Method Investment

We account for our private equity investment for which fair value is not readily determinable in accordance with APB Opinion No. 18, “The Equity Method of Accounting for Investments in Common Stock”. Each reporting period, we evaluate our investment for impairment if an event or circumstance occurs that is likely to have a significant adverse effect on the fair value of the investment. Examples of such events or circumstances include a significant deterioration in the business prospects of the investee; a significant adverse change in the economic or technological environment of the investee; and a significant doubt about the investee’s ability to continue as a going concern. If there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the cost method investment, the fair value of the investment is not calculated as it is not practicable to do so in accordance with paragraphs 14 and 15 of FASB Statement No. 107, “Disclosures about Fair Value of Financial Instruments.” If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. We have determined there are no impairment indicators present during 2005 on our cost method investment with a carrying value of \$5.0 million. This investment originated during fiscal year 2005 when we invested in a private company with blood processing technology under development. This investment is classified as other long-term assets in our consolidated balance sheets.

Property, Plant and Equipment

Property, Plant and Equipment is recorded at historical cost. We provide for depreciation and amortization by charges to operations using the straight-line method in amounts estimated to recover the cost of the building and improvements, equipment, and furniture and fixtures over their estimated useful lives as follows:

<u>Asset Classification</u>	<u>Estimated Useful Lives</u>
Building	30 Years
Building and leasehold improvements	5-25 Years
Plant equipment and machinery	3-10 Years
Office equipment and information technology	4-8 Years
Haemonetics equipment	2-4 Years

Depreciation expense was \$25.5 million, \$28.3 million and \$26.6 million for fiscal years 2005, 2004 and 2003, respectively.

Leasehold improvements are amortized over the lesser of their useful lives or the term of the lease. Maintenance and repairs are charged to operations as incurred. When equipment and improvements are sold or otherwise disposed of, the asset cost and accumulated depreciation are removed from the accounts, and the resulting gain or loss, if any, is included in the statements of income. Fully depreciated assets are removed from the accounts when they are no longer in use.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

Haemonetics Equipment

Our equipment is comprised of medical devices installed at customer sites. These devices remain our property. Generally the customer has the right to use it for a period of time as long as they meet the conditions we have established, which among other things, generally include one or more of the following:

- Purchase and consumption of a minimum level of disposable products
- Payment of monthly rental fees
- An asset utilization performance metric, such as performing a minimum level of procedures per month per device

Periodically we review the useful lives of our devices and perform reviews to determine if a group of these devices is impaired. To conduct these reviews we estimate the future amount and timing of demand for these devices. Changes in expected demand can result in additional depreciation expense, which is classified as cost of goods sold. Any significant unanticipated changes in demand could impact the value of our devices and our reported operating results. Expenditures for normal maintenance and repairs are charged to expense as incurred.

Accounting for Long-Lived Assets

Goodwill and Other Intangible Assets

We account for our intangible assets at historical cost. Intangible assets acquired in a business combination, including purchased research and development, are recorded under the purchase method of accounting at their estimated fair values at the date of acquisition. Goodwill represents the excess purchase price over the fair value of the net tangible and other identifiable intangible assets acquired. We amortize our other intangible assets over their useful lives, as applicable.

Goodwill and certain other intangible assets, determined to have an indefinite life, are not amortized. Instead these assets are reviewed for impairment at least annually in accordance with SFAS Statement No. 142, "Goodwill and Other Intangible Assets." We perform our annual impairment test on January 1st (or the first business day immediately following that date). As we only have one reporting unit, the test is based on a fair value approach, which uses our market capitalization as the basis reduced by the excess of the fair market value of our long-term debt over its carrying value, as identified in our assessment of interest rate risk of the entity as a whole. The test showed no evidence of impairment to our goodwill and other indefinite lived assets for fiscal 2005 or fiscal 2004.

We review our intangible assets and their related useful lives at least once a year to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. We conduct more frequent impairment assessments if certain conditions exist, including: a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the market place including changes in the prices paid for our products or changes in the size of the market for our products.

An impairment results if the carrying value of the asset exceeds the sum of the future undiscounted cash flows expected to result from the use and disposition of the asset. The amount of the impairment would be determined by comparing the carrying value to the fair value of the asset. Fair value is generally determined by calculating the present value of the estimated future cash flows using an appropriate discount rate. The projection of the future cash flows and the selection of a discount rate require significant management judgment. The key variables that management must estimate include sales volume, prices, inflation, product costs, capital expenditures and sales and marketing costs. For developed technology that has not been deployed we also must estimate the likelihood of both pursuing a particular strategy and the level of expected market adoption.

If the estimate of an intangible asset's remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

Research and Development Expenses

All research and development costs are expensed as incurred. Research and development expense was \$20.0 million for fiscal year 2005, \$17.4 million for fiscal year 2004 and \$19.5 million for fiscal year 2003.

Accounting for Shipping and Handling Costs

Shipping and handling costs are included in costs of goods sold with the exception of \$4.9 million for fiscal year 2005, and \$5.1 million for both fiscal years 2004 and 2003 that are included in selling, general and administrative expenses.

Income Taxes

In preparing our consolidated financial statements, the income tax provision is calculated for all jurisdictions in which we operate. This process involves estimating actual current taxes due plus assessing temporary differences arising from differing treatment for tax and accounting purposes that are recorded as deferred tax assets and liabilities. Deferred tax assets are periodically evaluated to determine their recoverability and a valuation allowance is established with a corresponding additional income tax provision recorded in our consolidated statements of income if their recovery is not considered likely. The provision for income taxes could also be materially impacted if actual taxes due differ from our earlier estimates. As of April 2, 2005, a \$0.4 million valuation allowance existed on our balance sheet. The total net deferred tax asset as of April 2, 2005 was \$13.8 million.

We file income tax returns in all jurisdictions in which we operate. We establish reserves to provide for additional income taxes that may be due in future years as these previously filed tax returns are audited. These reserves have been established based on management's assessment as to the potential exposure attributable to permanent differences and interest applicable to both permanent and temporary differences. All tax reserves are analyzed periodically and adjustments made as events occur that warrant modification.

Foreign Currency

We enter into forward exchange contracts to hedge the probable cash flows from forecasted inter company foreign currency denominated revenues, principally Japanese Yen and Euro. The purpose of our hedging strategy is to lock in foreign exchange rates for twelve months to minimize, for this period of time, the unforeseen impact on our results of operations of fluctuations in foreign exchange rates. We also enter into forward contracts that settle within 35 days to hedge certain inter-company receivables denominated in foreign currencies. These derivative financial instruments are not used for trading purposes. The forward exchange contracts are recorded at fair value and are included in other current assets or other current liabilities on our consolidated balance sheets. The gains or losses on the forward exchange contracts designated as hedges are recorded in net revenues on our consolidated statements of income when the underlying hedge transaction effects earning. The cash flows related to the gains and losses on these foreign currency hedges are classified in the consolidated statements of cash flows as part of cash flows from operating activities. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, the Company would reclassify the effective portion of any gain or loss on the related cash flow hedge from other comprehensive income to retained earnings at that time. The ineffective portion of a derivative's change in fair value is recognized currently in other income, net on our consolidated statements of income.

Accounting for Stock-Based Compensation

We have adopted the disclosure only provisions for employee stock-based compensation under SFAS Statement No. 148, "Accounting for Stock-Based Compensation – Transition and Disclosure," and continue to account for employee stock-based compensation using the intrinsic value method under APB Opinion No. 25, "Accounting for Stock Issued to Employees." Under APB Opinion No. 25, no accounting recognition is given to options granted to employees and directors at fair market value until they are exercised. Upon exercise, net proceeds, including tax benefits realized, are credited to equity. Had compensation costs under our stock-based compensation plans been determined based on the fair value model of SFAS Statement No. 123, as amended by SFAS Statement No. 148, the effect on our earnings per share would have been as follows:

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

	<u>April 2, 2005</u>	<u>April 3, 2004</u>	<u>March 29, 2003</u>
	(in thousands, except per share amounts)		
Net income (as reported):	\$ 39,639	\$ 29,320	\$ 28,379
Deduct: Total stock-based employee compensation expense determined under the fair value method for all awards, net of tax	<u>\$ (5,255)</u>	<u>\$ (4,938)</u>	<u>\$ (6,805)</u>
Pro Forma Net Income:	<u>\$ 34,384</u>	<u>\$ 24,382</u>	<u>\$ 21,574</u>
Earnings per share:			
Basic			
As Reported	\$ 1.55	\$ 1.20	\$ 1.15
Pro forma	\$ 1.35	\$ 1.00	\$ 0.88
Diluted			
As Reported	\$ 1.52	\$ 1.19	\$ 1.13
Pro forma	\$ 1.32	\$ 0.99	\$ 0.86

For purposes of the pro forma disclosure, any compensation cost on fixed awards with pro rata vesting is recognized on a straight-line basis over the award's vesting period and the fair value of each option is estimated on the date of grant using the Black-Scholes single option-pricing model with the following weighted average assumptions:

	<u>April 2, 2005</u>	<u>April 3, 2004</u>	<u>March 29, 2003</u>
Volatility	31.7%	29.0%	28.3%
Risk-Free Interest Rate	4.2%	3.6%	5.0%
Expected Life of Options	7 yrs.	7 yrs.	7 yrs.

The weighted average grant date fair value of options granted during 2005, 2004 and 2003 was approximately \$11.41 \$8.81 and \$13.13, respectively.

The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:

	<u>April 2, 2005</u>	<u>April 3, 2004</u>	<u>March 29, 2003</u>
Volatility	36.5%	32.5%	32.7%
Risk-Free Interest Rate	1.7%	1.3%	1.5%
Expected Life of Options	6 mos.	6 mos.	6 mos.

The weighted average grant date fair value of the six-month option inherent in the Purchase Plan was \$7.15, \$4.95 and \$7.11 in fiscal year 2005, 2004 and 2003, respectively. We have never paid cash dividends on shares of our common stock; accordingly there is no dividend yield for fiscal year 2005, 2004 or 2003.

New Accounting Pronouncements

On December 16, 2004, the FASB issued SFAS No. 123R (revised 2004), "Share-Based Payments", which is a revision of SFAS No. 123, "Accounting for Stock Based Compensation." SFAS No. 123R supersedes APB Opinion No. 25, "Accounting for Stock Issued to Employees". SFAS No.123R requires all share-based payments to employees, including grants of employee stock options, to be

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

recognized in the income statements based on their fair values. The disclosure only approach permitted by SFAS No. 123 and elected by us, is no longer an alternative effective with our fiscal year 2007. Accordingly, the adoption of SFAS No. 123R's fair value method will have a significant impact on the results of operations, although it will have no impact on our overall financial position. The impact of adoption of SFAS No. 123R cannot be predicted at this time because it will depend on levels of share-based payments granted in the future. We are currently evaluating which fair value method we will use to adopt the requirements of SFAS No. 123R. However, had we adopted SFAS No. 123R in prior periods, the impact of that standard would have approximated the impact of SFAS No. 123 as described in the disclosure of pro forma net income and earnings per share in Note 2 to our consolidated financial statements.

The FASB recently issued, FASB Statement No. 151, "Inventory Costs," ("SFAS No. 151") an amendment of ARB No. 43, Chapter 4. The amendment clarifies that abnormal amounts of idle facility expense, freight, handling costs, and wasted materials should be recognized as current-period charges. It also clarifies that the required allocation of fixed production overheads to inventory based on the normal capacity of the production facilities. We will adopt SFAS No. 151 on April 3, 2005 at the beginning of our fiscal year 2006. The clarification provided by SFAS No. 151 is consistent with our current accounting policy, and accordingly we expect no impact from the adoption of this statement.

In October 2004, the American Jobs Creation Act of 2004 ("AJCA") was enacted. The AJCA provides a deduction from income for qualified domestic production activities that will be phased in beginning in 2006 and fully implemented in 2010. The AJCA also provides a two-year phase-out for the existing extra-territorial income exclusion on foreign sales. In December 2004, the FASB issued FASB Staff Position ("FSP") No. 109-1, "Application of FASB Statement No. 109, Accounting for Income Taxes, to the Tax Deduction on Qualified Production Activities by the American Jobs Creation Act of 2004. It is our intent to maximize this deduction and we are currently evaluating the impact this will have on our future consolidated statements of income and financial position.

The AJCA also provides a temporary incentive for U.S. corporations to repatriate accumulated income earned abroad by providing an 85% dividends received deduction, provided certain criteria are met. At this time it is not practical to determine if this temporary incentive is appropriate for us or to estimate the amount of tax that would be required to be provided upon repatriation. Accordingly, until our evaluation is complete, we will not change our current intention to permanently reinvest accumulated earnings of our foreign subsidiaries.

Reclassifications

Since April 2003, we have invested in auction-rate securities. In fiscal year 2005, we concluded that it was appropriate to classify our auction rate securities as short term investments. Previously, such investments had been classified as cash and cash equivalents. Accordingly, we have revised the classification to report these securities as short-term investments in our fiscal year 2004 consolidated balance sheet by reclassifying \$38.7 million from Cash & Cash Equivalents to Short-term Investments. We held no auction rate securities in our portfolio at April 2, 2005. We have also made corresponding adjustments to our consolidated statements of cash flows to reflect the gross purchases and sales of these securities as investing activities rather than as a component of cash and cash equivalents. This change in classification does not affect previously reported cash flows from operations or from financing activities in our consolidated statements of cash flows or our previously reported consolidated statements of income for any period. Certain other reclassifications have been made to prior years' amounts to conform to the current year's presentation.

3. OTHER INTANGIBLE ASSET ACQUISITIONS AND INVESTMENTS

Other Technology

During the third quarter of fiscal year 2005, we entered into an exclusive license arrangement with a private company related to the use of its technology in our blood processing applications. We paid an initial \$0.6 million related to this license and made an investment in the private company of \$5.0 million. The total \$5.6 million is

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

classified as other long-term assets in our consolidated balance sheet. In connection with the agreement, future potential payments are payable if the technology reaches certain performance milestones. The potential payments total \$12.4 million and will be capitalized as other technology if paid. In addition, if the specified deliverables are completed, the agreement calls for minimum royalty payments for future commercial sales of products that incorporate this technology. The license is classified as “Other Technology” and is assigned an estimated useful life of 15 years.

Patents

During the second quarter of fiscal year 2005, we purchased \$4.0 million in patents for several products aimed at blood conservation and surgical blood salvage. The useful life assigned to the patents acquired was 10 years.

4. PRODUCT WARRANTIES

We provide a warranty on parts and labor for one year after the sale and installation of each device. We also warrant our disposable products through their use or expiration. We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.

	<u>April 2, 2005</u>	<u>April 3, 2004</u>
Warranty accrual as of the beginning of the period	\$ 677	\$ 1,056
Warranty Provision	2,348	1,882
Warranty Spending	<u>(2,322)</u>	<u>(2,261)</u>
Warranty accrual as of the end of the period	<u>\$ 703</u>	<u>\$ 677</u>

5. INVENTORIES, NET

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined on the first-in, first-out basis.

Inventories consist of the following:

	<u>April 2, 2005</u>	<u>April 3, 2004</u>
	(in thousands)	
Raw materials	\$ 12,388	\$ 11,630
Work-in-process	6,067	5,340
Finished goods	<u>34,633</u>	<u>35,265</u>
	<u>\$ 53,088</u>	<u>\$ 52,235</u>

6. GOODWILL AND OTHER INTANGIBLE ASSETS

The changes in the carrying amount of goodwill for fiscal year 2005, 2004 and 2003 are as follows (in thousands):

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

Carrying amount as of March 29, 2003	\$ 16,010
Effect of change in rates used for translation	<u>1,232</u>
Carrying amount as of April 3, 2004	17,242
Earn-out payment	1,020
Effect of change in rates used for translation	<u>(69)</u>
Carrying amount as of April 2, 2005	<u><u>\$ 18,193</u></u>

Other Intangible Assets

Other intangible assets include the value assigned to license rights and other technology, patents, customer contracts and relationships, software technology, and a trade name. The estimated useful lives for all of these intangible assets, excluding the trade name as it is considered to have an indefinite life, are 6 to 20 years. In fiscal year 2005, we recognized an impairment charge of \$1.7 million related to the excess of the carrying value over the fair market value of an intangible asset classified as Other Technology. The charge was included in amortization expense in our consolidated statements of income. The impairment was triggered by a re-evaluation of our plans to deploy such technology. As a result of our change in strategy, the carrying value of the intangible was reduced to zero.

Aggregate amortization expense for amortized other intangible assets for fiscal year 2005 is \$3.7 million. Additionally, expected future amortization expenses on other intangible assets approximate \$2.4 million for fiscal year 2006, \$2.8 million for fiscal year 2007, and \$2.7 million for fiscal years 2008 through 2010.

As of April 2, 2005

	<u>Gross Carrying Amount (in thousands)</u>	<u>Accumulated Amortization (in thousands)</u>	<u>Weighted Average Useful Life (in years)</u>
Amortized Intangibles			
Patents	\$ 10,389	\$ 2,321	14
Other technology	12,358	4,020	15
Customer contracts and related relationships	<u>11,909</u>	<u>2,986</u>	15
Subtotal	\$ 34,656	\$ 9,327	15
Indefinite Life Intangibles			
Trade name	<u>498</u>	<u>—</u>	Indefinite
Total Intangibles	<u><u>\$ 35,154</u></u>	<u><u>\$ 9,327</u></u>	

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

As of April 3, 2004

	<u>Gross Carrying Amount (in thousands)</u>	<u>Accumulated Amortization (in thousands)</u>	<u>Weighted Average Useful Life (in years)</u>
Amortized Intangibles			
Patents	\$ 6,371	\$ 1,594	14
Other technology	11,754	1,810	15
Customer contracts and related relationships	<u>11,738</u>	<u>2,165</u>	15
Subtotal	\$ 29,863	\$ 5,569	15
Indefinite Life Intangibles			
Trade name	<u>490</u>	<u>—</u>	Indefinite
Total Intangibles	<u>\$ 30,353</u>	<u>\$ 5,569</u>	

Another change to the net carrying value of our intangible assets from April 3, 2004 to April 2, 2005 was the effect of rate changes in the translation of the intangibles of our Canadian subsidiary.

7. NOTES PAYABLE AND LONG-TERM DEBT

Notes payable and long-term debt consists of the following:

	<u>April 2, 2005</u>	<u>April 3, 2004</u>
	(in thousands)	
Real estate mortgage	\$ 8,299	\$ 8,755
Senior notes	17,143	22,857
Haemonetics Japan Co. Ltd.	20,401	26,648
	<u>\$ 45,843</u>	<u>\$ 58,260</u>
Less – Current portion	26,612	32,818
	<u>\$ 19,231</u>	<u>\$ 25,442</u>

Real Estate Mortgage Agreement

In December 2000 we entered into a \$10.0 million real estate mortgage agreement (the “Mortgage Agreement”) with an investment firm. The Mortgage Agreement requires principal and interest payments of \$0.1 million per month for a period of 180 months, commencing February 1, 2001. The entire balance of the loan may be repaid at any time after February 1, 2006, subject to a prepayment premium, which is calculated based upon the change in the current weekly average yield of Ten (10)-year U.S. Treasury Constant Maturities, the principal balance due and the remaining loan term. The Mortgage Agreement provides for interest to accrue on the unpaid principal balance at a

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

rate of 8.41% per annum. Borrowings under the Mortgage Agreement are secured by the land, building and building improvements at our headquarters and manufacturing facility in the U.S. with a collective carrying value of approximately \$8.3 million and \$9.9 million as of April 2, 2005 and April 3, 2004, respectively. There are no financial covenants in the terms and conditions of this agreement.

Senior Notes

We have \$17.1 million of 7.05% Senior Notes due in 2007 (the “Senior Notes”). We are required to make annual prepayments of principal each year in the amount of \$5.7 million, which began October 15, 2001 and conclude with the final principal payment on October 15, 2007.

Interest on the Senior Notes is computed on the basis of a 360-day year of twelve 30-day months on the unpaid balance at the rate of 7.05% per annum, payable semiannually, on April 15 and October 15 each year. The Senior Notes contain affirmative and negative covenants and restrictions including but not limited to minimum stockholders’ equity and ratio requirements of consolidated funded indebtedness to consolidated total capitalization and priority indebtedness to consolidated stockholders equity.

Haemonetics Japan Co. Ltd.

At April 2, 2005, Haemonetics Japan Co. Ltd. had 2.2 billion Japanese Yen, equivalent to U.S. \$20.4 million, in unsecured debt outstanding. All of this debt is short term, maturing in less than 12 months.

Other Non-U.S. Borrowings

The weighted average short-term rates for U.S. and non-U.S. borrowings were 1.88%, 1.76% and 1.62% as of April 2, 2005, April 3, 2004 and March 29, 2003, respectively.

As of April 2, 2005, notes payable and long-term debts mature as follows:

Fiscal Year Ending	(in thousands)
2006	\$ 26,612
2007	6,254
2008	6,301
2009	638
2010	694
2011 and thereafter	5,344
	\$ 45,843

8. INCOME TAXES

Domestic and foreign income before provision for income tax is as follows:

	Years Ended		
	April 2, 2005	April 3, 2004	March 29, 2003
	(in thousands)		
Domestic	\$ 47,092	\$ 29,685	\$ 28,310
Foreign	12,749	16,127	10,297
Total	\$ 59,841	\$ 45,812	\$ 38,607

The income tax provision contains the following components:

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

	Years Ended		
	<u>April 2, 2005</u>	<u>April 3, 2004</u>	<u>March 29, 2003</u>
	(in thousands)		
<u>Current</u>			
Federal	\$ 9,875	\$ 8,459	\$ 1,092
State	1,663	946	981
Foreign	5,258	5,749	4,125
Total current	<u>\$ 16,796</u>	<u>\$ 15,154</u>	<u>\$ 6,198</u>
<u>Deferred</u>			
Federal	4,912	1,172	4,171
State	(420)	(33)	(193)
Foreign	(1,086)	199	52
Total deferred	<u>\$ 3,406</u>	<u>\$ 1,338</u>	<u>\$ 4,030</u>
Total tax expense	<u>\$ 20,202</u>	<u>\$ 16,492</u>	<u>\$ 10,228</u>

Included in the federal income tax provisions for fiscal years 2005, 2004 and 2003 are approximately \$1.1 million, \$0.6 million and \$0.4 million, respectively, provided on foreign source income of approximately \$3.1 million, \$1.7 million, and \$0.9 million for fiscal year 2005, 2004 and 2003, respectively, for taxes which are payable in the United States.

Tax effected, significant temporary differences comprising the net deferred tax asset (liability) are as follows:

	Years Ended	
	<u>April 2, 2005</u>	<u>April 3, 2004</u>
	(in thousands)	
Depreciation	\$ (2,373)	\$ (2,965)
Amortization	(2,639)	(3,004)
Inventory	7,829	15,530
Hedging	510	2,605
Accruals and reserves	4,405	1,950
Net operating loss carryforward	4,280	6,058
Tax credit carryforward	2,253	378
Gross Deferred Taxes	<u>\$ 14,265</u>	<u>\$ 20,552</u>
Less valuation allowance	(378)	(378)
Net deferred taxes	<u>\$ 13,887</u>	<u>\$ 20,174</u>

At April 2, 2005, we have approximately \$12.1 million in U.S. acquisition related net operating loss carryforwards subject to separate limitations that will expire beginning in 2019. We have \$3.1 million in federal and state tax credits subject to separate limitations that will expire beginning in 2007.

We file income tax returns in all jurisdictions in which we operate. We established reserves to provide for additional income taxes that may be due in future years as these previously filed tax returns are audited. These reserves have been established based on management's assessment as to the potential exposure attributable to permanent differences and interest applicable to both permanent and temporary differences. All tax reserves are analyzed periodically and adjustments made as events occur that warrant modification.

We do not provide U.S. taxes on our foreign subsidiaries' undistributed earnings as they are deemed to be permanently reinvested outside the U.S. Non-US income taxes are, however, provided on these foreign subsidiaries' undistributed earnings. Upon repatriation, we provide the appropriate U.S. income taxes on these earnings.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

The income tax provision from operations differs from tax provision computed at the 35% U.S. federal statutory income tax rate due to the following:

	<u>April 2, 2005</u>		<u>April 3, 2004</u> (in thousands)		<u>March 29, 2003</u>	
Tax at federal statutory rate	\$20,944	35.0%	\$16,034	35.0%	\$13,512	35.0%
Extraterritorial Income Exclusion	(1,198)	(2.0)	(659)	(1.4)	(1,961)	(5.1)
Difference between US and foreign tax	246	0.4	574	1.2	(1,522)	(3.9)
State income taxes net of federal benefit	668	1.1	593	1.3	512	1.3
Tax exempt interest	(594)	(1.0)	—	—	—	—
Other, net	136	0.3	(50)	(.1)	(313)	(0.8)
Reported income tax provision	<u>\$20,202</u>	33.8%	<u>16,492</u>	36.0%	<u>\$10,228</u>	26.5%

9. COMMITMENTS AND CONTINGENCIES

We lease facilities and certain equipment under operating leases expiring at various dates through fiscal year 2013. Facility leases require us to pay certain insurance expenses, maintenance costs and real estate taxes.

Approximate future basic rental commitments under operating leases as of April 2, 2005 are as follows:

Fiscal Year Ending	(in thousands)
2006	\$ 6,152
2007	3,634
2008	2,277
2009	1,120
2010	1,217
Thereafter	1,035
	<u>\$ 15,435</u>

Rent expense in fiscal year 2005, 2004 and 2003 was \$6.8 million, \$4.9 million and \$4.0 million respectively.

We are presently engaged in various legal actions, and although ultimate liability cannot be determined at the present time, we believe, based on consultation with counsel, that any such liability will not materially affect our consolidated financial position and results of operations.

On January 21, 2004 we filed a claim for binding arbitration against Baxter International, Inc., seeking an arbitration award that compels Baxter to honor its obligations to Haemonetics in the contracts it assumed, or to pay us damages. Provisions in our supply contracts signed with Alpha include protections in case of a change in ownership. In particular the contracts required that if Alpha were sold, the buyer must assume the obligations of the contracts. The arbitration panel issued its decision on May 20, 2005 and awarded the Company \$27.8 million in damages plus legal costs. We will record any amounts awarded in the period in which we are certain of the amount and that collection is probable.

As a result of our fiscal year 2005 license arrangement for blood processing technology, our fiscal year 2002 acquisition of Fifth Dimension, and our fiscal year 2002 agreement with Baxter related to pathogen reduction technology, we are contingently obligated to make certain payments. The fiscal year 2005 license arrangement

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

involves certain potential payments of up to \$12.4 million if the technology reaches certain performance milestones. In addition, if the specified deliverables are completed, the agreement calls for minimum royalty payments for future commercial sales of products that incorporate this technology. The Fifth Dimension acquisition involves certain potential payments of up to \$4.1 million (of which \$2.0 million has already been paid). Therefore our current potential obligation is \$2.1 million should sales of the Fifth Dimension software products exceed certain cumulative levels prior to the end of fiscal year 2008. The pathogen reduction agreement calls for us to make total potential payments of up to \$14.5 million as regulatory approvals are received in various markets. Out of the \$14.5 million of potential payments, we paid \$3.8 million in the fourth quarter of fiscal year 2003 as initial regulatory approvals were obtained in the European market. No payments were made in fiscal year 2005 or fiscal year 2004. If and when additional approvals are obtained, we will capitalize these payments as other technology, an intangible asset and amortize over their useful life.

10. FAIR VALUE OF FINANCIAL INSTRUMENTS

The fair value of cash and cash equivalents, receivables and short-term debt approximate their carrying value due to their short term maturities. As noted below, the fair value of our auction rate securities also approximates their carrying value due to their variable interest rates, which typically reset every 28 to 35 days. (See Note 2) The carrying value and estimated fair values of our other significant financial instruments are as follows:

<i>(in thousands)</i>	April 2, 2005		April 3, 2004	
	Carrying Value	Fair Value	Carrying Value	Fair Value
Assets				
Short term investments	—	—	\$ 38,650	\$ 38,650
Liabilities				
Long-term debt	\$ 19,231	\$ 20,866	\$ 25,442	\$ 28,057
Foreign exchange contracts	311	311	6,066	6,066
	\$ 19,542	\$ 21,177	\$ 31,508	\$ 34,123

The fair value of long term debt was calculated based upon the current market interest rates for debt of similar maturity and credit rating. The fair value of our foreign exchange contracts was based upon the market rates at the fiscal year end for the remaining life of the contract. The estimates provided are not necessarily indicative of the amounts we would realize in a current market exchange.

11. CAPITAL STOCK

Common Stock Repurchase Program

We made no stock repurchases during fiscal year 2005 and fiscal year 2004. During fiscal year 2003, we repurchased 1,850,150 shares of our outstanding common stock at an average prevailing price of \$27.11. This includes 829,700 shares repurchased under a 10b5-1 Plan, adopted March 29, 2002; 100,050 shares repurchased under a 10b5-1 Plan adopted July 29, 2002; and 427,600 shares repurchased under a 10b5-1 Plan adopted October 28, 2002. We expect any repurchased shares to be made available for issuance pursuant to our employee benefit and incentive plans and for other corporate purposes.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

On July 1, 2004, the Massachusetts Business Corporation Act (the “MBCA”) became effective and eliminated the concept of treasury shares. Under the MBCA, shares repurchased by Massachusetts corporations constitute authorized but unissued shares. As a result, at April 2, 2005, all of our shares in treasury were automatically retired reducing the number of common shares issued and outstanding. The value previously attributed to treasury shares was charged to additional paid-in capital and retained earnings. The amount allocated to additional paid-in-capital (APIC) was calculated as of April 2, 2005 based upon the average per share value of APIC (determined using the then number of shares outstanding) multiplied by the number of shares in treasury. The residual value was charged to retained earnings.

Stock Plans

We have a long-term incentive stock option plan, (the “Long-term Incentive Plan”) under which a maximum of 3,500,000 shares of our common stock may be issued pursuant to incentive and non-qualified stock options granted to our key employees, officers and directors. The Long-term Incentive Plan is administered by the Compensation Committee of the Board of Directors (the “Committee”) consisting of two or more independent members of our Board of Directors. The exercise price, for both incentive and non-qualified options granted under the Long-term Incentive Plan is determined by the Committee, but in no event shall such option price be less than the fair market value of the common stock at the time the option is granted. Options become exercisable in a manner determined by the Committee, generally over a four year period for employees and immediately at time of grant for non-employee directors, and all options expire not more than 10 years from the date of the grant. At April 2, 2005, there were 2,536,718 options outstanding under this plan and 612,375 shares available for future grant.

We had a non-qualified stock option plan under which options were granted to non-employee directors and two previous plans under which options were granted to key employees, consultants and advisors. During fiscal year 2005, 2004 and 2003, our recorded stock option compensation expense related to grants to consultants and advisors was immaterial. At April 2, 2005, there were 929,111 options outstanding related to these plans. No further options will be granted under these plans.

We have an Employee Stock Purchase Plan (the “Purchase Plan”) under which a maximum of 375,000 shares (subject to adjustment for stock splits and similar changes) of common stock may be purchased by eligible employees. Substantially all of our full-time employees are eligible to participate in the Purchase Plan.

The Purchase Plan provides for two “purchase periods” within each of our fiscal years, the first commencing on November 1 of each year and continuing through April 30 of the next calendar year, and the second commencing on May 1 of each year and continuing through October 31 of such year. Shares are purchased through an accumulation of payroll deductions (of not less than 2% nor more than 15% of compensation, as defined) for the number of whole shares determined by dividing the balance in the employee’s account on the last day of the purchase period by the purchase price per share for the stock determined under the Purchase Plan. The purchase price for shares is the lower of 85% of the fair market value of the common stock at the beginning of the purchase period, or 85% of such value at the end of the purchase period.

During fiscal year 2005, there were 42,381 shares purchased at prices ranging from \$19.60 to \$24.00 per share under the Purchase Plan. During fiscal year 2004, there were 57,807 shares purchased at prices ranging from \$14.86 to \$15.07 per share under the Purchase Plan. During fiscal year 2003, there were 36,997 shares purchased at prices ranging from \$18.03 to \$28.17 per share under the Purchase Plan. A summary of stock option activity for the three years ended April 2, 2005 is as follows:

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

	Shares	Weighted Average Exercise Price per Share
Outstanding at March 29, 2003	4,755,178	\$24.14
Granted	766,000	\$22.59
Exercised	(983,061)	\$17.46
Terminated	<u>(550,422)</u>	\$27.71
Outstanding at April 3, 2004	3,987,695	\$25.00
Granted	651,400	\$26.84
Exercised	(1,055,466)	\$23.93
Terminated	<u>(117,800)</u>	\$28.72
Outstanding at April 2, 2005	<u>3,465,829</u>	<u>\$25.54</u>
Exercisable at March 29, 2003	<u>2,841,486</u>	<u>\$20.83</u>
Exercisable at April 3, 2004	<u>2,576,042</u>	<u>\$23.61</u>
Exercisable at April 2, 2005	<u>2,107,683</u>	<u>\$24.58</u>

The following table summarizes information about stock options outstanding at April 2, 2005:

Range of Exercise Prices	Options Outstanding			Options Exercisable	
	Number Outstanding At April 2, 2005	Weighted Average Outstanding Contractual Life	Weighted Average Exercise Price	Number Exercisable At April 2, 2005	Weighted Average Exercise Price
\$15.16 – \$22.64	1,248,972	5.92	\$ 19.57	916,472	\$ 18.69
\$22.72 – \$30.19	1,162,192	7.57	\$ 25.79	553,638	\$ 25.31
\$30.39 – \$38.27	1,054,665	6.73	\$ 32.34	637,573	\$ 32.41
Total	<u>3,465,829</u>	<u>6.72</u>	<u>\$ 25.54</u>	<u>2,107,683</u>	<u>\$ 24.58</u>

12. EARNINGS PER SHARE (“EPS”)

The following table provides a reconciliation of the numerators and denominators reflected in the basic and diluted earnings per share computations, as required by SFAS No. 128, “Earnings Per Share,” (“EPS”).

Basic EPS is computed by dividing reported earnings available to stockholders by the weighted average shares outstanding. Diluted EPS also includes the effect of dilutive potential common shares.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

	<u>April 2, 2005</u>	<u>Years Ended April 3, 2004</u>	<u>March 29, 2003</u>
	(Dollars and shares in thousands except per share amounts)		
Basic EPS			
Net income	\$ 39,639	\$ 29,320	\$ 28,379
Weighted average shares	<u>25,523</u>	<u>24,435</u>	<u>24,591</u>
Basic income per share	<u>\$ 1.55</u>	<u>\$ 1.20</u>	<u>\$ 1.15</u>
Diluted EPS			
Net income	\$ 39,639	\$ 29,320	\$ 28,379
Basic weighted average shares	25,523	24,435	24,591
Dilutive effect of stock options	<u>622</u>	<u>260</u>	<u>457</u>
Diluted weighted average shares	26,145	24,695	25,048
Diluted income per share	<u>\$ 1.52</u>	<u>\$ 1.19</u>	<u>\$ 1.13</u>

During 2005, 2004 and 2003 approximately 0.5 million, 2.7 million and 2.1 million potentially dilutive common shares, respectively, were not included in the computation of diluted earnings per share because exercise prices were greater than the average market price of the common shares.

13. COMPREHENSIVE INCOME

Comprehensive income is the total of net income and all other non-owner changes in stockholders' equity. For us, all other non-owner changes are primarily foreign currency translation; the change in our net minimum pension liability and the changes in fair value of the effective portion of our outstanding cash flow hedge contracts.

The reconciliation of the components of accumulated other comprehensive loss is as follows:

<i>(in thousands):</i>	Foreign Currency Translation	Unrealized (loss) gain on derivatives (net of tax)	Minimum pension liability (net of tax)	Total
Balance as of March 29, 2003	\$ (10,654)	\$ (2,408)	\$ (424)	\$ (13,486)
Changes during the year	8,934	(2,018)	35	6,951
Balance as of April 3, 2004	<u>\$ (1,720)</u>	<u>\$ (4,426)</u>	<u>\$ (389)</u>	<u>\$ (6,535)</u>
Changes during the year	1,939	3,768	129	5,836
Balance as of April 2, 2005	<u>\$ 219</u>	<u>\$ (658)</u>	<u>\$ (260)</u>	<u>\$ (699)</u>

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

A summary of the components of other comprehensive income is as follows:

(In thousands)	Years Ended		
	April 2, 2005	April 3, 2004	March 29, 2003
Net income	\$ 39,639	\$ 29,320	\$ 28,379
Other comprehensive income:			
Foreign currency translation	1,939	8,934	8,028
Unrealized loss on cash flow hedges, net of tax	(80)	(8,973)	(7,519)
Reclassifications into earnings of cash flow hedge losses, net of tax	3,848	6,955	2,824
Minimum pension liabilities adjustment, net of tax	129	35	(424)
Total comprehensive income	\$ 45,475	\$ 36,271	\$ 31,288

14. RETIREMENT PLANS

Defined Contribution Plans

We have a Savings Plus Plan that is a 401(k) plan that allows our U.S. employees to accumulate savings on a pre-tax basis. In addition, matching contributions are made to the Plan based upon pre-established rates. Our matching contributions amounted to approximately \$1.9 million in 2005, \$1.8 million in 2004 and \$1.7 million in 2003. Upon Board approval, additional discretionary contributions can also be made. No discretionary contributions were made for the Savings Plan in fiscal year 2005, 2004 or 2003.

One of our subsidiaries also has a defined contribution plan. Both the employee and the employer make contributions to the plan. The employer contributions to this plan were \$0.4 million, \$0.5 million and \$0.6 million in fiscal year 2005, 2004 and 2003, respectively.

Defined Benefit Plans

Two of our subsidiaries have defined benefit pension plans covering substantially all full time employees at those subsidiaries. Net periodic benefit costs for the plans in the aggregate include the following components

	April 2, 2005	April 3, 2004	March 29, 2003
		(in thousands)	
Service cost	\$ 580	\$ 496	\$ 436
Interest cost on benefit obligation	157	129	125
Expected return on plan assets	(143)	(197)	155
Recognized net actuarial loss (gain)	85	176	(173)
Settlements	24	23	—
Amortization of unrecognized prior service cost	(37)	(35)	(66)
Amortization of unrecognized gain	47	53	20
Amortization of unrecognized initial obligation	23	22	20
	\$ 736	\$ 667	\$ 517

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

The activity under those defined benefit plans is as follows:

	<u>April 2, 2005</u>	<u>April 3, 2004</u>	<u>March 29, 2003</u>
Change in Benefit Obligation:			
Benefit Obligation, beginning of year	\$ (5,576)	\$ (4,087)	\$ (2,806)
Service cost	(580)	(496)	(436)
Interest cost	(157)	(129)	(125)
Benefits paid	244	64	18
Actuarial (gain) loss	86	(261)	(238)
Effect of special termination benefits	116	—	—
Currency translation	(353)	(667)	(500)
Benefit obligation, end of year	<u>\$ (6,220)</u>	<u>\$ (5,576)</u>	<u>\$ (4,087)</u>
Change in Plan Assets:			
Fair value of plan assets, beginning of year	\$ 3,001	\$ 2,017	\$ 1,600
Company contributions	518	467	419
Benefits paid	(220)	(41)	(18)
Actual (gain) loss on plan assets	143	197	(155)
Currency translation	(87)	361	171
Fair value of Plan Assets, end of year	<u>\$ 3,355</u>	<u>\$ 3,001</u>	<u>\$ 2,017</u>
Funded Status			
Unrecognized net actuarial loss	\$ (2,865)	\$ (2,575)	\$ (2,070)
Unrecognized initial obligation	661	905	645
Unrecognized prior service cost	271	303	284
Net amount recognized	<u>\$ (2,221)</u>	<u>\$ (1,702)</u>	<u>\$ (1,466)</u>
Amounts recognized on the balance sheet:			
Prepaid pension asset	\$ 414	\$ 304	\$ 188
Accrued pension liability	2,184	1,240	935
Accumulated other comprehensive items pre-tax	518	766	719
Net amount recognized	<u>\$ 3,116</u>	<u>\$ 2,310</u>	<u>\$ 1,842</u>

One of the benefit plans is funded through assets of the Company. Accordingly that plan has no assets included in the information presented above. The assets of the other plan are less than the accumulated benefit obligation.

The weighted average rates used to determine the net periodic benefit costs were as follows:

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

	<u>April 2, 2005</u>	<u>April 3, 2004</u>	<u>March 29, 2003</u>
Discount rate	2.9%	2.8%	3.0%
Rate of increased salary levels	1.9%	1.7%	1.3%
Expected long-term rate of return on assets	2.0%	2.0%	1.0%

We have no other material obligation for post-retirement or post-employment benefits.

15. TRANSACTIONS WITH RELATED PARTIES

We issue loans to employees for relocation costs and other personal purposes. The amount of these loans, which is included in other assets, amounted to approximately \$0.2 million, \$0.3 million and \$0.7 million in fiscal year 2005, 2004 and 2003, respectively. These loans are payable within five years. Certain loans are interest bearing, and interest income is recorded on these loans when collected. Certain loans have forgiveness provisions based upon continued service or compliance with various guidelines. The outstanding loan balance is amortized as a charge to operating expense as such amounts are forgiven.

Additionally, we have made two \$1.0 million earn-out payments to 6 Encore Inc. (formerly Fifth Dimension Information Systems, Inc.), in accordance with the Asset Purchase Agreement, dated December 12, 2001, as amended, in which Haemonetics Enterprises, Inc. and Haemonetics Canada Ltd. purchased the assets of Fifth Dimension Information Systems, Inc. The President and principal shareholder of 6 Encore Inc. is Brad Lazaruik, former Haemonetics Vice President, (President, Fifth Dimension division). The payments were made during fiscal year 2005 and 2003 respectively. There remains possible future payments to be made to 6 Encore Inc. of \$2.1 million if sales of certain software products exceed certain cumulative levels prior to the end of fiscal year 2008.

16. SEGMENT, GEOGRAPHIC AND CUSTOMER INFORMATION

Segment Definition Criteria

We manage our business on the basis of one operating segment: the design, manufacture and marketing of automated blood processing systems. Our chief operating decision-maker uses consolidated results to make operating and strategic decisions. Manufacturing processes, as well as the regulatory environment in which we operate, are largely the same for all product lines.

Product and Service Segmentation

We have two families of products: (1) those that serve the donor and (2) those that serve the patient. Under the donor family of products we have included blood bank, red cell and plasma collection products. The patient products are the surgical collection products.

Donor

The blood bank products include machines, single use disposables and solutions that perform “apheresis,” (the separation of whole blood into its components and subsequent collection of certain components, including platelets and plasma), as well as the washing of red blood cells for certain procedures. In addition, the blood bank product line includes solutions used in non-apheresis applications. The main devices used for these blood component therapies are the MCS®+ mobile collection system and the ACP® 215 automated cell processing system.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

Red cell products include machines and single use disposables and solutions that perform apheresis for the collection of red blood cells. Devices used for the collection of red blood cells are the MCS®+ 8150 mobile collection systems.

Plasma collection products are machines, disposables and solutions that perform apheresis for the separation of whole blood components and subsequent collection of plasma. The devices used in automated plasma collection are the PCS®2 plasma collection system and the Superlite™.

Patient

Surgical products include machines and single use disposables that perform surgical blood salvage in orthopedic and cardiovascular surgical applications. Surgical blood salvage is a procedure whereby shed blood is collected, cleansed and made available to be transfused back to the patient. The devices used in the surgical area are the OrthoPAT® and the Cell Saver® autologous blood recovery systems.

Other

Other revenue includes revenue generated from equipment repairs performed under preventative maintenance contracts or emergency service billings and miscellaneous sales, including revenue from our software division, Fifth Dimension, acquired on January 1, 2002. Fifth Dimension provides collection and data management systems to plasma collectors.

Revenues from External Customers:

Disposable Revenues by Product Family	Years ended (in thousands)		
	April 2, 2005	April 3, 2004	March 29, 2003
Donor:			
Blood Bank	\$ 130,427	\$ 112,209	\$ 99,921
Red Cell	28,676	22,321	15,542
Plasma	97,250	114,346	114,436
	<u>\$ 256,353</u>	<u>\$ 248,876</u>	<u>\$ 229,899</u>
Patient:			
Surgical	86,377	76,664	68,321
	<u>86,377</u>	<u>76,664</u>	<u>68,321</u>
Disposables revenue	\$ 342,730	\$ 325,540	\$ 298,220
Equipment	20,695	16,687	20,381
Misc & Service	20,173	22,002	18,355
	<u>20,173</u>	<u>22,002</u>	<u>18,355</u>
Total revenues from external customers	<u><u>\$ 383,598</u></u>	<u><u>\$ 364,229</u></u>	<u><u>\$ 336,956</u></u>

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

Geographic Segmentation

Years ended (in thousands)

April 2, 2005

	United States	Other North America	Total North America	Japan	Other Asia	Total Asia	Germany	France	United Kingdom	Italy	Austria	Other Europe	Total Europe	Total Consolidated
Sales	\$ 131,632	\$ 3,275	\$ 134,907	\$ 104,963	\$ 28,489	\$ 133,452	\$ 32,318	\$ 23,512	\$ 5,351	\$ 16,423	\$ 8,882	\$ 28,753	\$ 115,239	\$ 383,598
Total Assets	326,127	3,463	329,590	43,014	8,500	51,514	15,130	10,401	6,537	21,529	2,940	30,116	86,653	467,757
Long-Lived Assets	76,578	3,163	79,741	15,623	2,457	18,080	4,830	1,181	3,048	3,112	720	13,434	26,325	124,146

April 3, 2004

	United States	Other North America	Total North America	Japan	Other Asia	Total Asia	Germany	France	United Kingdom	Italy	Austria	Other Europe	Total Europe	Total Consolidated
Sales	\$ 126,872	\$ 3,271	\$ 130,143	\$ 99,626	\$ 27,129	\$ 126,755	\$ 33,489	\$ 20,666	\$ 3,556	\$ 13,936	\$ 8,332	\$ 27,352	\$ 107,331	\$ 364,229
Total Assets	269,743	3,354	273,097	48,314	8,363	56,677	13,698	11,401	6,225	19,577	2,821	23,898	77,620	407,394
Long-Lived Assets	82,728	3,050	85,778	18,316	2,294	20,610	5,209	1,509	3,030	2,380	882	6,547	19,557	125,945

March 29, 2003

	United States	Other North America	Total North America	Japan	Other Asia	Total Asia	Germany	France	United Kingdom	Italy	Austria	Other Europe	Total Europe	Total Consolidated
Sales	\$ 127,241	\$ 2,746	\$ 129,987	\$ 94,215	\$ 24,654	\$ 118,869	\$ 30,125	\$ 18,065	\$ 3,221	\$ 10,376	\$ 7,000	\$ 19,313	\$ 88,100	\$ 336,956
Total Assets	228,560	3,666	232,226	\$ 48,343	6,866	55,209	14,028	15,067	4,689	16,697	2,474	19,095	72,050	359,485
Long-Lived Assets	96,437	3,077	99,514	17,060	2,594	19,654	5,244	1,699	2,377	1,846	905	4,714	16,785	135,953

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (continued)

17. REORGANIZATION

On August 12, 2003, we announced a reorganization of our business into two global product families: donor and patient. This reorganization redefined our customer and allowed us to expand our customer base to better position us for future growth. As a result of the reorganization, we reduced our worldwide workforce of 1,500 employees by approximately 4%. No facilities were closed. The reductions resulted in a charge, included in selling, general and administrative expenses, for severance and related costs of \$2.7 million. A summary of activity follows (in thousands):

Balance as of March 29, 2003	\$ –
Total charges	2,690
Severance and related costs paid	2,690
Balance as of April 3, 2004	<u>\$ –</u>

18. SUMMARY OF QUARTERLY DATA (UNAUDITED)

	<u>First Quarter</u>	<u>Second Quarter</u>	<u>Third Quarter</u>	<u>Fourth Quarter**</u>
<i>Fiscal year ended April 2, 2005:</i>				
Net revenues	\$ 94,602	\$ 90,923	\$ 98,098	\$ 99,975
Gross profit	47,100	45,549	51,781	53,446
Operating income	14,962	13,911	15,300	15,670
Net income	9,820	8,874	11,007	9,938
Share data:				
Net Income:				
Basic	\$ 0.39	\$ 0.35	\$ 0.43	\$ 0.38
Diluted	\$ 0.38	\$ 0.34	\$ 0.42	\$ 0.37
<i>Fiscal year ended April 3, 2004:</i>				
Net revenues	\$ 88,283	\$ 87,488	\$ 90,737	\$ 97,721
Gross profit	39,835*	41,608*	43,390*	48,703*
Operating income	8,435*	9,134*	14,373*	15,351*
Net income	4,983	5,495	9,314	9,528
Share data:				
Net Income:				
Basic	\$ 0.21	\$ 0.23	\$ 0.38	\$ 0.38
Diluted	\$ 0.21	\$ 0.23	\$ 0.38	\$ 0.37

* Certain cost reductions were reclassified into gross profit from other income and expense so amounts differ from what was originally reported in fiscal year 2004.

** The fourth fiscal quarter of fiscal year 2004 includes 14 weeks due to our policy for determining our fiscal year end.

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Haemonetics Corporation:

We have audited the accompanying consolidated balance sheets of Haemonetics Corporation (a Massachusetts corporation) and its subsidiaries as of April 2, 2005 and April 3, 2004, and the related consolidated statements of income, stockholders' equity and cash flows for each of the three years in the period ended April 2, 2005. Our audits also included the financial statement schedule listed in the Index at Item 15(a). These financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Haemonetics Corporation and subsidiaries at April 2, 2005 and April 3, 2004, and the consolidated results of their operations and their cash flows for each of the three years in the period ended April 2, 2005, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the effectiveness of Haemonetics Corporation's internal control over financial reporting as of April 2, 2005, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated June 3, 2005 expressed an unqualified opinion thereon.

/s/ Ernst & Young LLP

Boston, Massachusetts

June 3, 2005

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None

ITEM 9A. CONTROLS AND PROCEDURES

A) Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, we conducted an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively) regarding the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15 of the Securities Exchange Act of 1934 (the "Exchange Act"). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that as of the end of the period covered by this report, our disclosure controls and procedures are effective to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to them by others within those entities.

B) Reports on Internal Control

Management's Annual Report on Internal Control over Financial Reporting

The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). The Company's internal control system was designed to provide reasonable assurance to the Company's management and Board of directors regarding the preparation and fair presentation of published financial statements.

The Company's management assessed the effectiveness of the Company's internal control over financial reporting as of April 2, 2005. In making this assessment, the management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework. Based on our assessment we believe that, as of April 2, 2005, the Company's internal control over financial reporting is effective based on those criteria.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management's assessment of the effectiveness of its internal control over financial reporting as of April 2, 2005 has been attested to by Ernst & Young LLP, an independent registered public accounting firm, as stated in their report which is included herein.

Report of Independent Registered Public Accounting Firm

The Board of Directors and Stockholders of Haemonetics Corporation:

We have audited management's assessment, included in the accompanying Management's Annual Report on Internal Control over Financial Reporting, that Haemonetics Corporation maintained effective internal control over financial reporting as of April 2, 2005, based on criteria established in Internal Control--Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). Haemonetics Corporation's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting. Our responsibility is to express an opinion on management's assessment and an opinion on the effectiveness of the company's internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, evaluating management's assessment, testing and evaluating the design and operating effectiveness of internal control, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, management's assessment that Haemonetics Corporation maintained effective internal control over financial reporting as of April 2, 2005, is fairly stated, in all material respects, based on the COSO criteria. Also, in our opinion, Haemonetics Corporation maintained, in all material respects, effective internal control over financial reporting as of April 2, 2005, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Haemonetics Corporation as of April 2, 2005 and April 3, 2004, and the related consolidated statements of income, stockholders' equity and cash flows for each of the three years in the period ended April 2, 2005 of Haemonetics Corporation and our report dated June 3, 2005 expressed an unqualified opinion thereon.

/s/ Ernst & Young LLP

Boston, Massachusetts
June 3, 2005

C) Changes in Internal Controls

There were no changes in the Company's internal control over financial reporting that occurred during the Company's most recently completed fiscal year that materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

ITEM 9B. OTHER INFORMATION

NONE

PART III

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

(a) The information concerning our directors and compliance with Section 16(a) of the Securities Exchange Act of 1934 required by this Item is incorporated by reference to our Proxy Statement for the Annual Meeting to be held July 27, 2005.

(b) The information concerning our Executive Officers is set forth at the end of Part I hereof.

(c) The balance of the information required by this item including information concerning our Audit Committee and the Audit Committee Financial Expert and compliance with Item 401 of S-K is incorporated by reference to the Company's Proxy Statement for the Annual Meeting to be held July 27, 2005. We have adopted a Code of Ethics that applies to our chief executive officer, chief financial officer and senior financial officers. The Code of Ethics is incorporated into the Company's Code of Business Conduct located on the Company's internet web site at <http://www.haemonetics.com/site/content/investor/investor.asp> and it is available in print to any shareholder who requests it. Such requests should be directed to our Company's Secretary.

We intend to disclose any amendment to, or waiver from, a provision of its code of ethics that applies to our chief executive officer, chief financial officer and senior financial officers and that relates to any element of the Code of Ethics definition enumerated in Item 406 of Regulation S-K by posting such information on our website.

ITEM 11. EXECUTIVE COMPENSATION

The information required by this Item is incorporated by reference in our Proxy Statement for the Annual Meeting to be held July 27, 2005.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The information required by this Item concerning security ownership of certain beneficial owners and management is incorporated by reference to the Company's Proxy Statement for the Annual Meeting to be held July 27, 2005

Stock Plans

The following table below sets forth information as of April 2, 2005 with respect to compensation plans under which equity securities of the Company are authorized for issuance.

Plan Category	(a) Number of securities to be issued upon exercise of outstanding options, warrants and rights	(b) Weighted average exercise price of outstanding options, warrants and rights	(c) Number of securities available for future issuance under equity compensation plans (excluding securities reflected in columns (a) (1)
Equity Compensation Plans approved by security holders	3,465,829	\$25.54	774,064
Equity compensation plans not approved by security holders	-0-	-0-	-0-
Total	3,465,829	\$25.54	774,064

(1) Includes 161,689 shares available for purchase under the Employee Stock Purchase Plan in future purchase periods.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

None.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required by this Item is incorporated by reference in our Proxy Statement for the Annual Meeting to be held July 27, 2005.

PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

The following documents are filed as a part of this report:

(a) Financial Statements are included in Part II of this report

Financial Statements required by Item 8 of this Form

Consolidated Statements of Income.....	36
Consolidated Balance Sheets	37
Consolidated Statements of Stockholders' Equity	38
Consolidated Statements of Cash Flows	39
Notes to Consolidated Financial Statements	40
Report of Independent Registered Public Accounting Firm	63

Schedules required by Article 12 of Regulation S-X

II Valuation and Qualifying Accounts	73
--	----

All other schedules have been omitted because they are not applicable or not required.

(b) Exhibits required by Item 601 of Regulation S-K are listed in the Exhibit Index at page 69, which is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HAEMONETICS CORPORATION

By: /s/ Brad Nutter
Brad Nutter, President
and Chief Executive Officer

Date: June 3, 2005

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<u>/s/ Ronald A. Matricaria</u> Ronald A. Matricaria	Chairman of the Board	June 3, 2005
<u>/s/ Brad Nutter</u> Brad Nutter	President and Chief Executive Officer, Director (Principal Executive Officer)	June 3, 2005
<u>/s/ Ronald J. Ryan</u> Ronald J. Ryan	Vice President and Chief Financial Officer, (Principal Financial Officer)	June 3, 2005
<u>/s/ Susan M. Hanlon</u> Susan M. Hanlon	Vice President Planning and Control (Principal Accounting Officer)	June 3, 2005
<u>/s/ Yutaka Sakurada</u> Yutaka Sakurada	President, Haemonetics Japan/Asia and Chairman and CEO, Haemonetics Japan Director	June 3, 2005
<u>/s/ Benjamin L. Holmes</u> Benjamin L. Holmes	Director	June 3, 2005
<u>/s/ Lawrence C. Best</u> Lawrence C. Best	Director	June 3, 2005
<u>/s/ Susan Bartlett Foote</u> Susan Bartlett Foote	Director	June 3, 2005
<u>/s/ Ronald G. Gelbman</u> Ronald G. Gelbman	Director	June 3, 2005
<u>/s/ Pedro Granadillo</u> Pedro Granadillo	Director	June 3, 2005

EXHIBITS FILED WITH SECURITIES AND EXCHANGE COMMISSION
Number and Description of Exhibit

3. Articles of Organization

3A* Articles of Organization of the Company effective August 29, 1985, as amended December 12, 1985 and May 21, 1987 (filed as Exhibit 3A to the Company's Form S-1 No. 33-39490 and incorporated herein by reference).

3B* Form of Restated Articles of Organization of the Company (filed as Exhibit 3B to the Company's Form S-1 No. 33-39490 and incorporated herein by reference).

3C* Articles of Amendment to the Articles of Organization of the Company filed May 8, 1991 with the Secretary of the Commonwealth of Massachusetts (filed as Exhibit 3E to the Company's Amendment No. 1 to Form S-1 No. 33-39490 and incorporated herein by reference).

3D* By-Laws of the Company, as amended March 31, 2005(filed as Exhibit 10.1 to the Company's Form 8-K No. 1-10730 dated April 6, 2005 and incorporated herein by reference).

4. Instruments defining the rights of security holders

4A* Specimen certificate for shares of common stock (filed as Exhibit 4B to the Company's Amendment No. 1 to Form S-1 No. 33-39490 and incorporated herein by reference).

10. Material Contracts

10A* The 1990 Stock Option Plan, as amended (filed as Exhibit 4A to the Company's Form S-8 No. 33-42006 and incorporated herein by reference).

10B* Form of Option Agreements for Incentive and Non-qualified Options (filed as Exhibit 10B to the Company's Form S-1 No. 33-39490 and incorporated herein by reference).

10C* Lease dated July 17, 1990 between the Buncher Company and the Company of property in Pittsburgh, Pennsylvania (filed as Exhibit 10K to the Company's Form S-1 No. 33-39490 and incorporated herein by reference).

10D* Lease dated July 3, 1991 between Wood Road Associates II Limited Partnership and the Company for the property adjacent to the main facility in Braintree, Massachusetts (filed as Exhibit 10M to the Company's Form 10-K No. 1-10730 for the year ended March 28, 1992 and incorporated herein by reference).

10E* Amendment No. 1 to Lease dated July 3, 1991 between Wood Road Associates II Limited Partnership and the Company for the child care facility (filed as Exhibit 10N to the Company's Form 10-K No. 1-10730 for the year ended March 28, 1992 and incorporated herein by reference).

10F* Amendment No. 2 to Lease dated July 3, 1991 between Wood Road Associates II Limited Partnership and the Company (filed as Exhibit 10S to the Company's Form 10-K No. 1-10730 for the year ended April 3, 1993 and incorporated herein by reference).

10G* Real Estate purchase agreement dated May 1, 1994 between 3M UK Holding PLC and the Company (filed as Exhibit 10AA to the Company's Form 10-K No. 1-10730 for the year ended April 1, 1995 and incorporated herein by reference).

10H* 1992 Long-Term Incentive Plan (filed as Exhibit 10V to the Company's Form 10-K No. 1-10730 for the year ended April 3, 1993 and incorporated herein by reference).

10I* Purchase agreement dated October 1, 1994 between Kuraray Co. and the Company (filed as Exhibit 10AC to the Company's Form 10-K No. 1-10730 for the year ended April 1, 1995 and incorporated herein by reference).

10J* First Amendment to lease dated July 17, 1990 between Buncher Company and the Company of property in Pittsburgh, Pennsylvania (filed as Exhibit 10AI to the Company's Form 10-Q No. 1-10730 for the quarter ended December 28, 1996 and incorporated herein by reference).

10K* Amendment, dated April 18, 1997 to the 1992 Long-Term Incentive Plan (filed as Exhibit 10V to the Company's Form 10-K No. 1-10730 for the year ended April 3, 1993 and incorporated herein by reference).

10L* Note Purchase agreement whereby Haemonetics Corporation authorized sale of \$40,000,000, 7.05% Senior Notes due October 15, 2007 (filed as Exhibit 10A to the Company's Form 10-Q No. 1-10730 for the quarter ended September 27, 1997 and incorporated herein by reference).

10M* 1998 Employee Stock Purchase Plan (filed as Exhibit 10Z to the Company's Form 10-K No. 1-10730 for the year ended March 28, 1998 and incorporated herein by reference).

10N* 1998 Stock Option Plan for Non-Employee Directors. (filed as Exhibit 10AA to the Company's Form 10-K No. 1-10730 for the year ended March 28, 1998 and incorporated herein by reference).

10O* Lease, dated July 29, 1997 between New Avon Limited Partnership and the Company for the property in Avon, Massachusetts (filed as Exhibit 10AB to the Company's Form 10-K No. 1-10730 for the year ended March 28, 1998 and incorporated herein by reference).

10P* Agreement and Plan of Merger dated September 4, 2000 between Haemonetics Corporation and Transfusion Technologies Corporation (filed as Exhibit 2.1 to the Company's Form 8-K No. 1-14041 dated September 29, 2000 and incorporated herein by reference).

10Q* Amendment dated September 29, 2000 to the 7.05% Senior Notes (filed as Exhibit 10A to the Company's Form 10-Q No. 1-10730 for the quarter ended September 30, 2000 and incorporated herein by reference).

10R* Haemonetics Corporation 2000 Long-term Incentive Plan (filed as Exhibit 10A to the Company's Form 10-Q No. 1-10730 for the quarter ended December 30, 2000 and incorporated herein by reference).

10S* Note and Mortgage dated December 12, 2000 between the Company and General Electric Capital Business Asset Funding Corporation relating to the Braintree facility (filed as Exhibit 10B to the Company's Form 10-Q No. 1-10730 for the quarter ended December 30, 2000 and incorporated herein by reference).

10T* Amendment No. 3 to Lease dated July 3, 1991 between Wood Road Associates II Limited Partnership and the Company, dated April 1, 1997 (filed as Exhibit 10AA to the Company's Form 10-K No. 1-10730 for the year ended March 30, 2002 and incorporated herein by reference).

10U* Amendment No. 4 to Lease dated July 3, 1991 between Wood Road Associates II Limited Partnership, as assigned to Trinet Essential Facilities XXIX, Inc., effective June 18, 1998, and the Company, dated February 25, 2002. (filed as Exhibit 10AB to the Company's Form 10-K No. 1-10730 for the year ended March 30, 2002 and incorporated herein by reference).

10V* Employment Agreement between the Company and Ronald J. Ryan. (filed as Exhibit 10.2 to the Company's Form 10-Q No. 1-10730 for the quarter ended June 29, 2002 and incorporated herein by reference).

10W* Employment agreement between Brad Nutter and Haemonetics Corporation. (filed as Exhibit 10AE to the Company's Form 10-K No. 1-10730 for the year ended March 29, 2003 and incorporated herein by reference).

10X * First Amendment of lease dated July 29, 1997 between New Avon Limited Partnership and the Company for the property in Avon, Massachusetts. (filed as Exhibit 10AF to the Company's Form 10-K No. 1-10730 for the year ended March 29, 2003 and incorporated herein by reference).

10Y * Second Amendment to lease dated July 17, 1990 between Buncher Company and the Company for the property in Pittsburgh, Pennsylvania.(filed as Exhibit 10AG to the Company's Form 10-K No. 1-10730 for the year ended March 29, 2003 and incorporated herein by reference).

10Z* Form of Option Agreements for Non-Qualified stock options for the 1992 Long-Term Incentive Plan for Employees. (filed as Exhibit 10AH to the Company's Form 10-K No. 1-10730 for the year ended March 29, 2003 and incorporated herein by reference).

10AA* Form of Option Agreements for Non-Qualified stock options for the 1998 Stock Option Plan for Non-Employee Directors. (filed as Exhibit 10AI to the Company's Form 10-K No. 1-10730 for the year ended March 29, 2003 and incorporated herein by reference).

10AB* Form of Option Agreement for Non-Qualified stock options for the 2000 Long Term-Incentive Plan for Employees. (filed as Exhibit 10AJto the Company's Form 10-K No. 1-10730 for the year ended March 29, 2003 and incorporated herein by reference).

10AC* Form of Option Agreements for Non-Qualified stock options for the 2000 Long- Term Incentive Plan for Non-Employee Directors. (filed as Exhibit 10AK to the Company's Form 10-K No. 1-10730 for the year ended March 29, 2003 and incorporated herein by reference).

10AD* Employment Agreement between the Company and Robert Ebbeling. (filed as Exhibit 10AL to the Company's Form 10-K No. 1-10730 for the year ended March 29, 2003.)

10AE* Employment agreement between the Company and Peter Allen (filed as Exhibit 10.1 to the Company's Form 10-Q No 1-10730 for the quarter ended September 27, 2003 and incorporated herein by reference).

10AF* Employment agreement between the Company and Brian Concannon (filed as Exhibit 10.2 to the Company's Form 10-Q No 1-10730 for the quarter ended September 27, 2003 and incorporated herein by reference).

10AG* Employment agreement between the Company and Alicia Lopez (filed as Exhibit 10.3 to the Company's Form 10-Q No 1-10730 for the quarter ended September 27, 2003 and incorporated herein by reference).

10AH* Second Amendment of lease dated July 29, 1997 between New Avon Limited Partnership and the Company for the property in Avon, Massachusetts(filed as Exhibit 10AM to the Company's Form 10-K No 1-10730 for the year ended April 3, 2004 and incorporated herein by reference).

10AI* Third Amendment of lease dated July 29, 1997 between New Avon Limited Partnership and the Company for the property in Avon, Massachusetts (filed as Exhibit 10AN to the Company's Form 10-K No 1-10730 for the year ended April 3, 2004 and incorporated herein by reference).

10AJ* Summary of the Employment Agreement between Haemonetics Corporation and Dr. Ulrich Exckert (filed as Exhibit 10AO to the Company's Form 10-K No 1-10730 for the year ended April 3, 2004 and incorporated herein by reference).

10AK Amendment dated April 22, 2005 to the 7.05% Senior Notes.

21 Subsidiaries of the Company

23.1 Consent of the Independent Registered Public Accounting Firm

31.1 Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002, of Brad Nutter, President and Chief Executive Officer of the Company

31.2 Certification pursuant to Section 302 of Sarbanes-Oxley of 2002, of Ronald J. Ryan, Vice President and Chief Financial Officer of the Company

32.1 Certification Pursuant to 18 United States Code Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of Brad Nutter, President and Chief Executive Officer of the Company

32.2 Certification Pursuant to 18 United States Code Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of Ronald J. Ryan, Vice President and Chief Financial Officer of the Company

* Incorporated by reference

(All other exhibits are inapplicable.)

SCHEDULE II

HAEMONETICS CORPORATION

VALUATION AND QUALIFYING ACCOUNTS
(in thousands)

	<u>Balance at Beginning of Period</u>	<u>Charged to Costs and Expenses</u>	<u>Charged to Other Accounts</u>	<u>Write-Offs (Net of Recoveries)</u>	<u>Balance at End of Period</u>
For Year Ended April 2, 2005					
Allowance for Doubtful Accounts	\$ 2,261	\$ 782	\$ —	\$ (969)	\$ 2,074
For Year Ended April 3, 2004					
Allowance for Doubtful Accounts	\$ 1,449	\$ 809	\$ —	\$ 3	\$ 2,261
For Year Ended March 29, 2003					
Allowance for Doubtful Accounts	\$ 1,298	\$ 149	\$ —	\$ 2	\$ 1,449
Purchase Accounting Reserves	\$ 44	\$ (44)	\$ —	\$ —	\$ —

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statements (Nos. 33-42005, 33-42006, 33-70932, 33-70934, 33-80652, 333-61453, 333-61455, 333-60020 and 333-62598) of our reports dated June 3, 2005, with respect to the consolidated financial statements and schedule of Haemonetics Corporation, Haemonetics Corporation management's assessment of the effectiveness of internal control over financial reporting, and the effectiveness of internal control over financial reporting of Haemonetics Corporation included in the Annual Report (Form 10-K) for the year ended April 2, 2005.

/s/ Ernst & Young LLP

Boston, Massachusetts
June 3, 2005

CORPORATE DIRECTORY

Haemonetics Corporation

Corporate Headquarters
400 Wood Road
Braintree, MA 02184 USA
Phone: 781-848-7100
Fax: 781-356-3558
Web: www.haemonetics.com

Building 18, Avenue C
Buncher Industrial Park
Leetsdale, PA 15056 USA
Phone: 412-741-7399
Fax: 412-741-7458

155 Medical Sciences Drive
Union, SC 29379 USA
Phone: 864-427-6293
Fax: 864-427-1668

Haemonetics Austria

Handelsgesellschaft m.b.H
Berlagasse 45/B2-02
1210 Wien Austria
Phone: +43-1-294-2900
Fax: +43-1-294-2905

Haemonetics SA-NV

Complex Planet II
Leuvensesteenweg 542/14
1930 Zaventem Belgium
Phone: +32-2-720-7484
Fax: +32-2-720-7155
Web: www.haemonetics.be

Fifth Dimension Information Systems

A Haemonetics Company
Suite 500, 10025-102A Avenue
Edmonton, Alberta T5J 2Z2
Canada
Phone: 780-425-6560
Fax: 780-420-6562
Web: www.5d.ca

Haemonetics Medical Devices (Shanghai) Trading Co., Ltd.

Room 032.28F.HSBC Tower
101 Yin Cheng Rd. (E)
Shanghai 200120
People's Republic of China
Phone: +86-21-5066-3366
Fax: +86-21-6841-3688

Haemonetics CZ, spol. s.r.o

Ptašinského 8
602 00 Brno Czech Republic
Phone: +42-054121-2400
Fax: +42-054121-2399

Haemonetics France S.A.R.L.

46 bis rue Pierre Curie
Z.I. des Gâtines
78370 Plaisir France
Phone: +33-1-308-141-41
Fax: +33-1-308-141-30

Haemonetics GmbH

Wolfratshauer Straße 84
81379 Munich Germany
Phone: +49-89-785-8070
Fax: +49-89-780-9779
Web: www.haemonetics.de

Haemonetics Hong Kong Ltd.

Suite 1314, 13/Floor
Two Pacific Place
88 Queensway Hong Kong
Phone: +852-28689218
Fax: +852-28014380

Haemonetics Italia S.R.L.

Via Donizetti, 30
20020 Lainate – Milan Italy
Phone: +39-02-935-70113
Fax: +39-02-935-72132
Web: www.haemonetics.it

Haemonetics Japan K.K.

Kyodo Building
16-banchi, Ichiban-cho
Chiyoda-ku
Tokyo 102-0083 Japan
Phone: +81-3-3237-7260
Fax: +81-3-3237-7330
Web: www.haemonetics.co.jp

Haemonetics BV

Tinstraat 107
NL-4823 AA Breda
The Netherlands
Phone: 0031-765449477
Fax: 0031-765449357
Web: www.haemonetics.nl

Haemonetics Scandinavia AB

Ideon Retahuset
S-223 70 Lund Sweden
Phone: +46-46286-2320
Fax: +46-46286-2321
Web: www.haemonetics.se

Haemonetics S.A.

Signy Center
P.O. Box 262
1274 Signy 2 Switzerland
Phone: +41-22-363-9011
Fax: +41-22-363-9054

Haemonetics Asia Inc.

Taiwan Branch
26F-1, No. 102
Roosevelt Road Section 2
Taipei Taiwan
Phone: +886-2-2369-0722
Fax: +886-2-2364-3698

Haemonetics Ltd.

Beechwood House,
Beechwood Estate
Elmete Lane, Roundhay
Leeds LS8 2LQ United Kingdom
Phone: +44-113-273-7711
Fax: +44-113-273-4055

5 Ashley Drive
Bothwell
G71 8BS
Strathclyde Scotland
Phone: +44-1698-819700
Fax: +44-1698-811811

INVESTOR INFORMATION

Stock Listing

The Company's stock is traded on the New York Stock Exchange under the symbol HAE.

NYSE Certification

In 2004, Haemonetics submitted to the New York Stock Exchange the required annual CEO certification stating that the CEO was not aware of any violation by the Company of the NYSE corporate governance listing standards.

Transfer Agent and Registrar

Inquiries concerning the transfer of shares, lost stock certificates, duplicate mailings or change of address should be directed to:

Registrar and Transfer Company
10 Commerce Drive
Cranford, NJ 07016 USA
Phone: 800-368-5948
E-mail: info@rtco.com

Auditors

Ernst & Young LLP
Boston, MA USA

Annual Meeting

The Annual Meeting of the Stockholders will be held at the Company's headquarters at 400 Wood Road, Braintree, MA USA on July 27, 2005.

Investor Relations

Julie Fallon
Director, Investor Relations &
Corporate Communications
fallon@haemonetics.com
Phone: 781-356-9517

Haemonetics' Trademarks

5D, ACP, BSC, Blood Stream, cardioPAT, Cell Saver, Chairside Separator, CollectFirst, CritScan, Cymbal, Fifth Dimension, Haemolite, Haemonet, Haemonetics, Haemonetics Cell Saver, Haemonetics MCS, Haemonetics PCS, Haemonetics Ultralite, MCS, MCS Pro, OrthoPAT, PCS, Smartsuction, Total Apheresis & Design, Ultralite.

HAEMONETICS®

400 Wood Road, Braintree, Massachusetts, USA 02184-9114
781.848.7100 / www.haemonetics.com
